{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 56725, "items": [{"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T21:51:55Z", "timestamp": 1574459515706}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "5", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clin Pharmacol Ther"], "published-print": {"date-parts": [[1994, 5]]}, "DOI": "10.1038/clpt.1994.69", "type": "journal-article", "created": {"date-parts": [[2010, 8, 30]], "date-time": "2010-08-30T13:33:18Z", "timestamp": 1283175198000}, "page": "556-562", "source": "Crossref", "is-referenced-by-count": 116, "title": ["Pharmacodynamics and pharmacokinetics of khat: A controlled study"], "prefix": "10.1038", "volume": "55", "author": [{"given": "Peter", "family": "Widler", "sequence": "first", "affiliation": []}, {"given": "Karoline", "family": "Mathys", "sequence": "additional", "affiliation": []}, {"given": "Rudolf", "family": "Brenneisen", "sequence": "additional", "affiliation": []}, {"given": "Peter", "family": "Kalix", "sequence": "additional", "affiliation": []}, {"given": "Hans-Ulrich", "family": "Fisch", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["Clinical Pharmacology and Therapeutics"], "deposited": {"date-parts": [[2015, 2, 11]], "date-time": "2015-02-11T16:19:48Z", "timestamp": 1423671588000}, "score": 38.36452, "issued": {"date-parts": [[1994, 5]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1994, 5]]}, "issue": "5"}, "alternative-id": ["clpt199469"], "URL": "http://dx.doi.org/10.1038/clpt.1994.69", "ISSN": ["0009-9236", "1532-6535"], "issn-type": [{"value": "0009-9236", "type": "print"}, {"value": "1532-6535", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T03:06:07Z", "timestamp": 1574564767445}, "reference-count": 78, "publisher": "Wiley", "issue": "1", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 274, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Mov Disord."], "published-print": {"date-parts": [[2015, 1]]}, "DOI": "10.1002/mds.26082", "type": "journal-article", "created": {"date-parts": [[2014, 12, 1]], "date-time": "2014-12-01T16:18:45Z", "timestamp": 1417450725000}, "page": "64-72", "source": "Crossref", "is-referenced-by-count": 77, "title": ["Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics"], "prefix": "10.1002", "volume": "30", "author": [{"given": "Peter A.", "family": "LeWitt", "sequence": "first", "affiliation": [{"name": "Parkinson's Disease and Movement Disorders Center; Henry Ford Hospital; West Bloomfield; Michigan; and the Department of Neurology; Wayne State University School of Medicine; Detroit Michigan USA"}]}], "member": "311", "published-online": {"date-parts": [[2014, 12, 1]]}, "reference": [{"key": "10.1002/mds.26082-BIB0001|mds26082-cit-0001", "doi-asserted-by": "crossref", "first-page": "374", "DOI": "10.1056/NEJM196702162760703", "article-title": "Aromatic amino acids and modification of parkinsonism", "volume": "276", "author": "Cotzias", "year": "1967", "journal-title": "N Engl J Med"}, {"key": "10.1002/mds.26082-BIB0002|mds26082-cit-0002", "doi-asserted-by": "crossref", "first-page": "337", "DOI": "10.1056/NEJM196902132800701", "article-title": "Modification of Parkinsonism: chronic treatment with l-dopa", "volume": "280", "author": "Cotzias", "year": "1969", "journal-title": "N Engl J Med"}, {"key": "10.1002/mds.26082-BIB0003|mds26082-cit-0003", "doi-asserted-by": "crossref", "first-page": "997", "DOI": "10.1002/mds.20243", "article-title": "Levodopa in the treatment of Parkinson's disease: the second consensus meeting", "volume": "19", "author": "Olanow", "year": "2004", "journal-title": "Mov Disord"}, {"key": "10.1002/mds.26082-BIB0004|mds26082-cit-0004", "doi-asserted-by": "crossref", "first-page": "1200", "DOI": "10.1038/1801200a0", "article-title": "3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists", "volume": "180", "author": "Carlsson", "year": "1957", "journal-title": "Nature"}, {"issue": "Suppl 2", "key": "10.1002/mds.26082-BIB0005|mds26082-cit-0005", "doi-asserted-by": "crossref", "first-page": "S249", "DOI": "10.1007/s00415-010-5741-y", "article-title": "A brief history of levodopa", "volume": "257", "author": "Hornykiewicz", "year": "2010", "journal-title": "J Neurol"}, {"key": "10.1002/mds.26082-BIB0006|mds26082-cit-0006", "doi-asserted-by": "crossref", "first-page": "67", "DOI": "10.3181/00379727-51-13831", "article-title": "The effects of intravenous injection of L-dopa upon blood pressure", "volume": "51", "author": "Oster", "year": "1942", "journal-title": "Proc Soc Exp Biol Med"}, {"key": "10.1002/mds.26082-BIB0007|mds26082-cit-0007", "doi-asserted-by": "crossref", "first-page": "28", "DOI": "10.1007/BF00738347", "article-title": "\u00dcber das sympathetikomimetische pressorische Prinzip des Hirns (\u201cUrosympathin\u201d)", "volume": "204", "author": "Holtz", "year": "1947", "journal-title": "Arch Exp Path Pharmak"}, {"key": "10.1002/mds.26082-BIB0008|mds26082-cit-0008", "author": "LeWitt", "first-page": "325", "year": "1989", "volume-title": "Handbook of Experimental Pharmacology, vol 88"}, {"key": "10.1002/mds.26082-BIB0009|mds26082-cit-0009", "author": "Hornykiewicz", "first-page": "393", "year": "1970", "volume-title": "L-dopa and Parkinsonism"}, {"key": "10.1002/mds.26082-BIB0010|mds26082-cit-0010", "doi-asserted-by": "crossref", "first-page": "75", "DOI": "10.1016/j.bbr.2014.05.009", "article-title": "Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat", "volume": "270", "author": "Ostock", "year": "2014", "journal-title": "Behav Brain Res"}, {"key": "10.1002/mds.26082-BIB0011|mds26082-cit-0011", "doi-asserted-by": "crossref", "first-page": "177", "DOI": "10.1016/j.bcp.2007.01.036", "article-title": "Norepinephrine: the redheaded stepchild of Parkinson's disease", "volume": "74", "author": "Rommelfanger", "year": "2007", "journal-title": "Biochem Pharmacol"}, {"key": "10.1002/mds.26082-BIB0012|mds26082-cit-0012", "doi-asserted-by": "crossref", "first-page": "19", "DOI": "10.1016/0028-3908(85)90090-5", "article-title": "Partial lesions of the nigrostriatal pathway in the rat: acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs", "volume": "24", "author": "Hefti", "year": "1985", "journal-title": "Neuropharmacology"}, {"key": "10.1002/mds.26082-BIB0013|mds26082-cit-0013", "doi-asserted-by": "crossref", "first-page": "117", "DOI": "10.1016/S0163-7258(02)00325-X", "article-title": "L-3,4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system", "volume": "97", "author": "Misu", "year": "2003", "journal-title": "Pharmacol Ther"}, {"key": "10.1002/mds.26082-BIB0014|mds26082-cit-0014", "author": "Misu", "first-page": "23", "year": "2006", "volume-title": "Neurobiology of DOPA as a Neurotransmitter"}, {"key": "10.1002/mds.26082-BIB0015|mds26082-cit-0015", "doi-asserted-by": "crossref", "first-page": "638", "DOI": "10.1016/j.lfs.2011.08.008", "article-title": "L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease", "volume": "89", "author": "King", "year": "2011", "journal-title": "Life Sci"}, {"key": "10.1002/mds.26082-BIB0016|mds26082-cit-0016", "doi-asserted-by": "crossref", "first-page": "1742", "DOI": "10.1046/j.1471-4159.1995.64041742.x", "article-title": "Iron-mediated oxidation of 3,4-dihydroxyphenylalanine to an excitotoxin", "volume": "64", "author": "Newcomer", "year": "1995", "journal-title": "J Neurochem"}, {"key": "10.1002/mds.26082-BIB0017|mds26082-cit-0017", "doi-asserted-by": "crossref", "first-page": "582", "DOI": "10.1016/j.expneurol.2013.02.009", "article-title": "Dual effects of L-DOPA on nigral dopaminergic neurons", "volume": "247", "author": "Guatteo", "year": "2013", "journal-title": "Exp Neurol"}, {"key": "10.1002/mds.26082-BIB0018|mds26082-cit-0018", "doi-asserted-by": "crossref", "first-page": "347", "DOI": "10.1002/jnr.23318", "article-title": "5-S-cysteinyldopamine neurotoxicity: influence on the expression of \u03b1-synuclein and ERp57 in cellular and animal models of Parkinson's disease", "volume": "92", "author": "Aureli", "year": "2014", "journal-title": "J Neurosci Res"}, {"key": "10.1002/mds.26082-BIB0019|mds26082-cit-0019", "doi-asserted-by": "crossref", "first-page": "35", "DOI": "10.1097/00002826-198403000-00002", "article-title": "Pharmacokinetics of levodopa", "volume": "7", "author": "Nutt", "year": "1984", "journal-title": "Clin Neuropharmacol"}, {"key": "10.1002/mds.26082-BIB0020|mds26082-cit-0020", "doi-asserted-by": "crossref", "first-page": "258", "DOI": "10.1002/ana.410200212", "article-title": "Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography", "volume": "20", "author": "Leenders", "year": "1986", "journal-title": "Ann Neurol"}, {"key": "10.1002/mds.26082-BIB0021|mds26082-cit-0021", "doi-asserted-by": "crossref", "first-page": "401", "DOI": "10.1007/s11064-007-9442-6", "article-title": "The role of 3-O-methyldopa in the side effects of L-DOPA", "volume": "33", "author": "Lee", "year": "2008", "journal-title": "Neurochem Res"}, {"key": "10.1002/mds.26082-BIB0022|mds26082-cit-0022", "doi-asserted-by": "crossref", "first-page": "207", "DOI": "10.1016/B978-0-12-381326-8.00009-0", "article-title": "Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease", "volume": "95", "author": "Kaakkola", "year": "2010", "journal-title": "Int Rev Neurobiol"}, {"key": "10.1002/mds.26082-BIB0023|mds26082-cit-0023", "doi-asserted-by": "crossref", "first-page": "537", "DOI": "10.1002/ana.410180505", "article-title": "Effect of carbidopa on pharmacokinetics of intravenously administered levodopa: implications for mechanism of action of carbidopa in the treatment of Parkinsonism", "volume": "13", "author": "Nutt", "year": "1985", "journal-title": "Ann Neurol"}, {"key": "10.1002/mds.26082-BIB0024|mds26082-cit-0024", "doi-asserted-by": "crossref", "first-page": "153", "DOI": "10.1097/00002826-198604000-00006", "article-title": "Effect of supplemental carbidopa on bioavailability of L-dopa", "volume": "9", "author": "Cedarbaum", "year": "1986", "journal-title": "Clin Neuropharmacol"}, {"key": "10.1002/mds.26082-BIB0025|mds26082-cit-0025", "doi-asserted-by": "crossref", "first-page": "198", "DOI": "10.1212/WNL.34.2.198", "article-title": "L-dopa decarboxylation in chronically treated patients", "volume": "34", "author": "Ward", "year": "1984", "journal-title": "Neurology"}, {"key": "10.1002/mds.26082-BIB0026|mds26082-cit-0026", "doi-asserted-by": "crossref", "first-page": "41", "DOI": "10.1046/j.1365-2125.1997.00610.x", "article-title": "Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics", "volume": "44", "author": "Dingemanse", "year": "1997", "journal-title": "Br J Clin Pharmacol"}, {"key": "10.1002/mds.26082-BIB0027|mds26082-cit-0027", "doi-asserted-by": "crossref", "first-page": "631", "DOI": "10.1097/00001756-199902250-00034", "article-title": "Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats", "volume": "10", "author": "Tanaka", "year": "1999", "journal-title": "Neuroreport"}, {"key": "10.1002/mds.26082-BIB0028|mds26082-cit-0028", "first-page": "189", "article-title": "The site of dopamine formation in rat striatum after L-dopa administration", "volume": "217", "author": "Hefti", "year": "1981", "journal-title": "J Pharmacol Exp Ther"}, {"key": "10.1002/mds.26082-BIB0029|mds26082-cit-0029", "doi-asserted-by": "crossref", "first-page": "1980", "DOI": "10.1212/01.wnl.0000312381.29287.ff", "article-title": "Results from a phase I safety trial of hAADC gene therapy for Parkinson disease", "volume": "70", "author": "Eberling", "year": "2008", "journal-title": "Neurology"}, {"key": "10.1002/mds.26082-BIB0030|mds26082-cit-0030", "doi-asserted-by": "crossref", "first-page": "377", "DOI": "10.1089/hum.2011.220", "article-title": "Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease", "volume": "23", "author": "Mittermeyer", "year": "2012", "journal-title": "Hum Gene Ther"}, {"key": "10.1002/mds.26082-BIB0031|mds26082-cit-0031", "doi-asserted-by": "crossref", "first-page": "1138", "DOI": "10.1016/S0140-6736(13)61939-X", "article-title": "Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial", "volume": "383", "author": "Palfi", "year": "2014", "journal-title": "Lancet Neurol"}, {"key": "10.1002/mds.26082-BIB0032|mds26082-cit-0032", "doi-asserted-by": "crossref", "first-page": "152", "DOI": "10.1212/WNL.0b013e3181a0feba", "article-title": "MAO-B inhibitor know-how: back to the pharm", "volume": "72", "author": "LeWitt", "year": "2009", "journal-title": "Neurology"}, {"key": "10.1002/mds.26082-BIB0033|mds26082-cit-0033", "doi-asserted-by": "crossref", "first-page": "109", "DOI": "10.2165/00003088-200645020-00001", "article-title": "Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update", "volume": "45", "author": "Nyholm", "year": "2006", "journal-title": "Clin Pharmacokinet"}, {"key": "10.1002/mds.26082-BIB0034|mds26082-cit-0034", "doi-asserted-by": "crossref", "first-page": "1319", "DOI": "10.1002/mds.22587", "article-title": "Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies", "volume": "24", "author": "LeWitt", "year": "2009", "journal-title": "Mov Disord"}, {"key": "10.1002/mds.26082-BIB0035|mds26082-cit-0035", "doi-asserted-by": "crossref", "first-page": "100", "DOI": "10.1212/WNL.36.1.100", "article-title": "Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators", "volume": "36", "author": "Melamed", "year": "1986", "journal-title": "Neurology"}, {"issue": "11 Suppl 2", "key": "10.1002/mds.26082-BIB0036|mds26082-cit-0036", "first-page": "25", "article-title": "Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies", "volume": "39", "author": "Yeh", "year": "1989", "journal-title": "Neurology"}, {"key": "10.1002/mds.26082-BIB0037|mds26082-cit-0037", "doi-asserted-by": "crossref", "first-page": "385", "DOI": "10.1007/BF00315415", "article-title": "Pharmokinetics and effects of levodopa in advanced Parkinson's disease", "volume": "39", "author": "Bredberg", "year": "1990", "journal-title": "Eur J Clin Pharmacol"}, {"issue": "11 Suppl 2", "key": "10.1002/mds.26082-BIB0038|mds26082-cit-0038", "first-page": "45", "article-title": "Controlled release carbidopa/levodopa (Sinemet 50/200 CR-4). Clinical, pharmacokinetic, and pharmacodynamic studies", "volume": "39", "author": "LeWitt", "year": "1989", "journal-title": "Neurology"}, {"issue": "11 Suppl 2", "key": "10.1002/mds.26082-BIB0039|mds26082-cit-0039", "first-page": "38", "article-title": "A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100)", "volume": "39", "author": "Cedarbaum", "year": "1989", "journal-title": "Neurology"}, {"key": "10.1002/mds.26082-BIB0040|mds26082-cit-0040", "doi-asserted-by": "crossref", "first-page": "94", "DOI": "10.1111/bcp.12324", "article-title": "Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets", "volume": "78", "author": "Othman", "year": "2014", "journal-title": "Br J Clin Pharmacol"}, {"key": "10.1002/mds.26082-BIB0041|mds26082-cit-0041", "doi-asserted-by": "crossref", "first-page": "59", "DOI": "10.1007/s002280050161", "article-title": "Population pharmacokinetics of oral levodopa in parkinsonian patients", "volume": "51", "author": "Triggs", "year": "1996", "journal-title": "Eur J Clin Pharmacol"}, {"key": "10.1002/mds.26082-BIB0042|mds26082-cit-0042", "doi-asserted-by": "crossref", "first-page": "610", "DOI": "10.1067/mcp.2000.106795", "article-title": "Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone", "volume": "67", "author": "Jorga", "year": "2000", "journal-title": "Clin Pharmacol Ther"}, {"key": "10.1002/mds.26082-BIB0043|mds26082-cit-0043", "doi-asserted-by": "crossref", "first-page": "307", "DOI": "10.1007/s10928-005-0039-x", "article-title": "Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease", "volume": "32", "author": "Chan", "year": "2005", "journal-title": "J Pharmacokin Pharmacodynam"}, {"key": "10.1002/mds.26082-BIB0044|mds26082-cit-0044", "doi-asserted-by": "crossref", "first-page": "686", "DOI": "10.1002/ana.10189", "article-title": "Evolution of the response to levodopa during the first four years of therapy", "volume": "51", "author": "Nutt", "year": "2002", "journal-title": "Ann Neurol"}, {"key": "10.1002/mds.26082-BIB0045|mds26082-cit-0045", "doi-asserted-by": "crossref", "first-page": "367", "DOI": "10.1212/WNL.43.2.367", "article-title": "Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease", "volume": "43", "author": "Contin", "year": "1993", "journal-title": "Neurology"}, {"key": "10.1002/mds.26082-BIB0046|mds26082-cit-0046", "doi-asserted-by": "crossref", "first-page": "1418", "DOI": "10.1212/WNL.58.9.1418", "article-title": "Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics", "volume": "58", "author": "Kompoliti", "year": "2002", "journal-title": "Neurology"}, {"key": "10.1002/mds.26082-BIB0047|mds26082-cit-0047", "doi-asserted-by": "crossref", "first-page": "726", "DOI": "10.1212/WNL.42.4.726", "article-title": "Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology", "volume": "42", "author": "Edwards", "year": "1992", "journal-title": "Neurology"}, {"key": "10.1002/mds.26082-BIB0048|mds26082-cit-0048", "doi-asserted-by": "crossref", "first-page": "1041", "DOI": "10.1002/mds.1203", "article-title": "Gastric emptying time and gastric motility in patients with Parkinson's disease", "volume": "16", "author": "Hardoff", "year": "2001", "journal-title": "Mov Disord"}, {"key": "10.1002/mds.26082-BIB0049|mds26082-cit-0049", "doi-asserted-by": "crossref", "first-page": "47", "DOI": "10.1111/j.1365-2125.1990.tb03601.x", "article-title": "The influence of levodopa on gastric emptying in man", "volume": "29", "author": "Robertson", "year": "1990", "journal-title": "Br J Clin Pharmacol"}, {"key": "10.1002/mds.26082-BIB0050|mds26082-cit-0050", "first-page": "CD008453", "article-title": "Helicobacter pylori eradication for Parkinson's disease", "volume": "11", "author": "Rees", "year": "2011", "journal-title": "Cochrane Database Syst Rev"}, {"key": "10.1002/mds.26082-BIB0051|mds26082-cit-0051", "doi-asserted-by": "crossref", "first-page": "2974", "DOI": "10.1007/s00415-013-7089-6", "article-title": "Motor fluctuations and Helicobacter pylori in Parkinson's disease", "volume": "260", "author": "Rahne", "year": "2013", "journal-title": "J Neurol"}, {"key": "10.1002/mds.26082-BIB0052|mds26082-cit-0052", "doi-asserted-by": "crossref", "first-page": "96", "DOI": "10.1097/WNF.0000000000000037", "article-title": "Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection", "volume": "37", "author": "Naro\u017ca\u0144ska", "year": "2014", "journal-title": "Clin Neuropharmacol"}, {"key": "10.1002/mds.26082-BIB0053|mds26082-cit-0053", "doi-asserted-by": "crossref", "first-page": "1241", "DOI": "10.1002/mds.25522", "article-title": "The role of small intestinal bacterial overgrowth in Parkinson's disease", "volume": "28", "author": "Fasano", "year": "2013", "journal-title": "Mov Disord"}, {"key": "10.1002/mds.26082-BIB0054|mds26082-cit-0054", "doi-asserted-by": "crossref", "first-page": "89", "DOI": "10.1097/00002826-200203000-00006", "article-title": "Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations", "volume": "25", "author": "Nyholm", "year": "2002", "journal-title": "Clin Neuropharmacol"}, {"key": "10.1002/mds.26082-BIB0055|mds26082-cit-0055", "doi-asserted-by": "crossref", "first-page": "483", "DOI": "10.1056/NEJM198402233100802", "article-title": "The \u201con-off\u201d phenomenon in Parkinson's disease: relation to levodopa absorption and transport", "volume": "310", "author": "Nutt", "year": "1984", "journal-title": "N Engl J Med"}, {"key": "10.1002/mds.26082-BIB0056|mds26082-cit-0056", "doi-asserted-by": "crossref", "first-page": "61", "DOI": "10.1111/j.1365-2125.1989.tb03506.x", "article-title": "The effect of age on the pharmacokinetics of levodopa in patients with Parkinson's disease", "volume": "28", "author": "Robertson", "year": "1989", "journal-title": "Eur J Clin Pharmacol"}, {"key": "10.1002/mds.26082-BIB0057|mds26082-cit-0057", "doi-asserted-by": "crossref", "first-page": "463", "DOI": "10.1007/BF00626370", "article-title": "Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease", "volume": "41", "author": "Contin", "year": "1991", "journal-title": "Eur J Clin Pharmacol"}, {"key": "10.1002/mds.26082-BIB0058|mds26082-cit-0058", "doi-asserted-by": "crossref", "first-page": "91", "DOI": "10.1097/00002826-198904000-00002", "article-title": "Pharmacokinetic and pharmacodynamic modeling of levodopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet", "volume": "12", "author": "Nelson", "year": "1989", "journal-title": "Clin Neuropharmacol"}, {"key": "10.1002/mds.26082-BIB0059|mds26082-cit-0059", "doi-asserted-by": "crossref", "first-page": "463", "DOI": "10.2165/00003088-199630060-00004", "article-title": "Pharmacokinetic optimization in the treatment of Parkinson's disease", "volume": "30", "author": "Contin", "year": "1996", "journal-title": "Clin Pharmacokinet"}, {"key": "10.1002/mds.26082-BIB0060|mds26082-cit-0060", "doi-asserted-by": "crossref", "first-page": "70", "DOI": "10.1212/WNL.40.1.70", "article-title": "Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa /levodopa (Sinemet CR4) in Parkinson's disease", "volume": "40", "author": "Nelson", "year": "1990", "journal-title": "Neurology"}, {"key": "10.1002/mds.26082-BIB0061|mds26082-cit-0061", "first-page": "231", "article-title": "L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects", "volume": "46", "author": "Muenter", "year": "1971", "journal-title": "Mayo Clin Proc"}, {"key": "10.1002/mds.26082-BIB0062|mds26082-cit-0062", "doi-asserted-by": "crossref", "first-page": "763", "DOI": "10.1212/WNL.52.4.763", "article-title": "Loss of long-duration response to levodopa over time in PD: implications for wearing-off", "volume": "52", "author": "Zappia", "year": "1999", "journal-title": "Neurology"}, {"key": "10.1002/mds.26082-BIB0063|mds26082-cit-0063", "doi-asserted-by": "crossref", "first-page": "587", "DOI": "10.1016/j.parkreldis.2011.03.014", "article-title": "The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications", "volume": "17", "author": "Anderson", "year": "2011", "journal-title": "Parkinsonism Relat Disord."}, {"key": "10.1002/mds.26082-BIB0064|mds26082-cit-0064", "doi-asserted-by": "crossref", "first-page": "389", "DOI": "10.1002/ana.410380308", "article-title": "The subacute levodopa test for evaluating long-duration response in Parkinson's disease", "volume": "38", "author": "Quattrone", "year": "1995", "journal-title": "Ann Neurol"}, {"key": "10.1002/mds.26082-BIB0065|mds26082-cit-0065", "doi-asserted-by": "crossref", "first-page": "1264", "DOI": "10.1111/j.1471-4159.1980.tb09969.x", "article-title": "Changes in neocortical dopamine concentrations in response to levodopa infusions", "volume": "34", "author": "Doller", "year": "1980", "journal-title": "J Neurochem"}, {"key": "10.1002/mds.26082-BIB0066|mds26082-cit-0066", "doi-asserted-by": "crossref", "first-page": "515", "DOI": "10.1016/S0306-4522(99)00294-8", "article-title": "Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment", "volume": "94", "author": "Cenci", "year": "1999", "journal-title": "Neuroscience"}, {"key": "10.1002/mds.26082-BIB0067|mds26082-cit-0067", "doi-asserted-by": "crossref", "first-page": "90", "DOI": "10.1016/j.neulet.2011.03.087", "article-title": "Differential expression of FosB, c-Fos, and Zif268 in forebrain regions after acute or chronic L-DOPA treatment in a rat model of Parkinson's disease", "volume": "496", "author": "Ebihara", "year": "2011", "journal-title": "Neurosci Lett"}, {"key": "10.1002/mds.26082-BIB0068|mds26082-cit-0068", "doi-asserted-by": "crossref", "first-page": "250", "DOI": "10.1016/j.nbd.2013.09.014", "article-title": "Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway", "volume": "62", "author": "Riverol", "year": "2014", "journal-title": "Neurobiol Dis"}, {"key": "10.1002/mds.26082-BIB0069|mds26082-cit-0069", "doi-asserted-by": "crossref", "first-page": "375", "DOI": "10.1007/s00221-010-2372-6", "article-title": "Movement chunking during sequence learning. Is a dopamine-dependent process: a study conducted in Parkinson's disease", "volume": "205", "author": "Tremblay", "year": "2010", "journal-title": "Exp Brain Res"}, {"key": "10.1002/mds.26082-BIB0070|mds26082-cit-0070", "doi-asserted-by": "crossref", "first-page": "2468", "DOI": "10.1056/NEJMct0800326", "article-title": "Levodopa for the treatment of Parkinson's disease", "volume": "359", "author": "LeWitt", "year": "2008", "journal-title": "N Engl J Med"}, {"key": "10.1002/mds.26082-BIB0071|mds26082-cit-0071", "doi-asserted-by": "crossref", "first-page": "346", "DOI": "10.1016/S1474-4422(13)70025-5", "article-title": "Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial", "volume": "12", "author": "Hauser", "year": "2013", "journal-title": "Lancet Neurol"}, {"key": "10.1002/mds.26082-BIB0072|mds26082-cit-0072", "doi-asserted-by": "crossref", "first-page": "75", "DOI": "10.1002/mds.25742", "article-title": "Double-blind study of an actively-transported levodopa prodrug, XP21279, in Parkinson disease", "volume": "29", "author": "LeWitt", "year": "2014", "journal-title": "Mov Disord"}, {"key": "10.1002/mds.26082-BIB0073|mds26082-cit-0073", "doi-asserted-by": "crossref", "first-page": "198", "DOI": "10.1097/WNF.0b013e3181de8924", "article-title": "Factors associated with motor fluctuations and dyskinesia in Parkinson disease: potential role of a new melevodopa plus carbidopa formulation (Sirio)", "volume": "33", "author": "Stocchi", "year": "2010", "journal-title": "Clin Neuropharmacol"}, {"issue": "suppl 1", "key": "10.1002/mds.26082-BIB0074|mds26082-cit-0074", "first-page": "S248", "article-title": "Accordion Pill carbidopa/levodopa (AP CD/LD) for treatment of advanced Parkinson's disease (PD)", "volume": "29", "author": "LeWitt", "year": "2014", "journal-title": "Mov Disord."}, {"issue": "35", "key": "10.1002/mds.26082-BIB0075|mds26082-cit-0075", "first-page": "67", "article-title": "Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease", "volume": "012", "author": "Chen", "journal-title": "Clin Neuropharmacol."}, {"issue": "suppl 1", "key": "10.1002/mds.26082-BIB0076|mds26082-cit-0076", "first-page": "S239", "article-title": "Pharmacokinetics (PK) following inhaled levodopa delivery with CVT-301: Rapid augmentation of systemic levodopa (LD) levels and improvement in motor function in PD patients with motor fluctuations", "volume": "29", "author": "Freed", "year": "2014", "journal-title": "Mov Disord."}, {"issue": "suppl 1", "key": "10.1002/mds.26082-BIB0077|mds26082-cit-0077", "first-page": "S162", "article-title": "Constant therapeutic levodopa (LD) plasma concentrations maintained by continuous subcutaneous (SC) administration of ND-0612, a novel formulation of LD/carbidopa (CD)", "volume": "28", "author": "Caraco", "year": "2013", "journal-title": "Mov Disord"}, {"key": "10.1002/mds.26082-BIB0078|mds26082-cit-0078", "doi-asserted-by": "crossref", "first-page": "2731", "DOI": "10.1093/brain/awu195", "article-title": "The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa", "volume": "137", "author": "Cilia", "year": "2014", "journal-title": "Brain"}], "container-title": ["Movement Disorders"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fmds.26082", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/mds.26082", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 5]], "date-time": "2018-08-05T22:56:46Z", "timestamp": 1533509806000}, "score": 29.181402, "subtitle": ["Levodopa Pharmacokinetics and Pharmacodynamics"], "issued": {"date-parts": [[2014, 12, 1]]}, "references-count": 78, "journal-issue": {"published-print": {"date-parts": [[2015, 1]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.1002/mds.26082", "relation": {"cites": []}, "ISSN": ["0885-3185"], "issn-type": [{"value": "0885-3185", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T07:26:51Z", "timestamp": 1575271611715}, "reference-count": 0, "publisher": "Oxford University Press", "isbn-type": [{"value": "9780198784906", "type": "print"}, {"value": "9780191827143", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2018, 12]]}, "abstract": "<p>The non-vitamin K antagonist oral anticoagulants (NOACs) (or direct-acting oral anticoagulants) are a novel class of direct-acting oral anticoagulants developed to offer more predictable pharmacodynamic and pharmacokinetic properties compared to vitamin K antagonists. Due to their predictable relation between drug dose and anticoagulant effect, NOACs are used at a fixed dose, without routine monitoring of coagulation parameters. While the use of a fixed dose greatly enhances the convenience of anticoagulant therapy, physicians need to understand the pharmacokinetic and pharmacodynamic aspects of NOACs to identify those patients for whom a dosage adjustment is required.</p>", "DOI": "10.1093/med/9780198784906.003.0055", "type": "book-chapter", "created": {"date-parts": [[2018, 3, 28]], "date-time": "2018-03-28T15:58:22Z", "timestamp": 1522252702000}, "page": "264-268", "source": "Crossref", "is-referenced-by-count": 0, "title": ["The NOACs: pharmacodynamics and pharmacokinetics"], "prefix": "10.1093", "author": [{"given": "Thomas", "family": "Vanassche", "sequence": "additional", "affiliation": []}, {"given": "Peter", "family": "Verhamme", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2018, 7]]}, "container-title": ["ESC CardioMed"], "original-title": ["The NOACs: pharmacodynamics and pharmacokinetics"], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T15:59:23Z", "timestamp": 1574870363000}, "score": 29.181402, "editor": [{"given": "Raffaele", "family": "DeCaterina", "sequence": "first", "affiliation": []}], "issued": {"date-parts": [[2018, 7]]}, "ISBN": ["9780198784906", "9780191827143"], "references-count": 0, "URL": "http://dx.doi.org/10.1093/med/9780198784906.003.0055"}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T06:09:32Z", "timestamp": 1574143772530}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "1", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2002]]}, "DOI": "10.1023/a:1015724919784", "type": "journal-article", "created": {"date-parts": [[2002, 12, 29]], "date-time": "2002-12-29T00:56:06Z", "timestamp": 1041123366000}, "page": "95-97", "source": "Crossref", "is-referenced-by-count": 0, "prefix": "10.1007", "volume": "29", "author": [{"given": "Peter", "family": "Blood", "sequence": "first", "affiliation": []}], "member": "297", "container-title": ["Journal of Pharmacokinetics and Pharmacodynamics"], "deposited": {"date-parts": [[2012, 12, 28]], "date-time": "2012-12-28T14:03:42Z", "timestamp": 1356703422000}, "score": 26.998125, "issued": {"date-parts": [[2002]]}, "references-count": 0, "journal-issue": {"issue": "1"}, "alternative-id": ["372979"], "URL": "http://dx.doi.org/10.1023/a:1015724919784", "ISSN": ["1567-567X"], "issn-type": [{"value": "1567-567X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T11:40:47Z", "timestamp": 1574422847060}, "reference-count": 67, "publisher": "Wiley", "issue": "4", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1813, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2010, 10]]}, "DOI": "10.1111/j.1365-2125.2010.03680.x", "type": "journal-article", "created": {"date-parts": [[2010, 4, 12]], "date-time": "2010-04-12T08:01:23Z", "timestamp": 1271059283000}, "page": "471-480", "source": "Crossref", "is-referenced-by-count": 39, "title": ["Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview"], "prefix": "10.1111", "volume": "70", "author": [{"given": "Hans-Peter", "family": "Lipp", "sequence": "first", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2010, 9, 14]]}, "reference": [{"key": "10.1111/j.1365-2125.2010.03680.x-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "1610", "DOI": "10.1086/523576", "article-title": "Posaconazole: a broad-spectrum triazole antifungal agent", "volume": "45", "author": "Nagappan", "year": "2007", "journal-title": "Clin Infect Dis"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "218", "DOI": "10.1046/j.1365-2125.2003.01977.x", "article-title": "Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults", "volume": "57", "author": "Courtney", "year": "2003", "journal-title": "Br J Clin Pharmacol"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "7", "DOI": "10.1111/j.1439-0507.2008.01523.x", "article-title": "Antifungal agents - clinical pharmacokinetics and drug interactions", "volume": "51", "author": "Lipp", "year": "2008", "journal-title": "Mycoses"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "1862", "DOI": "10.1016/j.clinthera.2007.09.015", "article-title": "Posaconazole: an extended-spectrum triazole antifungal agent", "volume": "29", "author": "Schiller", "year": "2007", "journal-title": "Clin Ther"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "1553", "DOI": "10.2165/00003495-200565110-00007", "article-title": "Posaconazole", "volume": "65", "author": "Keating", "year": "2005", "journal-title": "Drugs"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "77", "DOI": "10.1038/sj.clpt.6100230", "article-title": "Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo", "volume": "83", "author": "Templeton", "year": "2008", "journal-title": "Clin Pharmacol Ther"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "180", "DOI": "10.1124/jpet.104.082826", "article-title": "CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions", "volume": "314", "author": "Galetin", "year": "2005", "journal-title": "J Pharmacol Exp Ther"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "541", "DOI": "10.1128/AAC.01123-08", "article-title": "Comprehensive in vitro inhibition analysis of 8 cytochrome P450 (CYP) enzymes by voriconazole: major effect on CYPs 2B6, 2C9, 2C19 and 3A", "volume": "53", "author": "Jeong", "year": "2008", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "2788", "DOI": "10.1128/AAC.47.9.2788-2795.2003", "article-title": "Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults", "volume": "47", "author": "Courtney", "year": "2003", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "1627", "DOI": "10.1592/phco.27.12.1627", "article-title": "Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease", "volume": "27", "author": "Krishna", "year": "2007", "journal-title": "Pharmacotherapy"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "17", "DOI": "10.1093/jac/dkm389", "article-title": "Antifungal serum concentration monitoring: an update", "volume": "61", "author": "Goodwin", "year": "2008", "journal-title": "J Antimicrob Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "233", "DOI": "10.1128/AAC.41.2.233", "article-title": "Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae", "volume": "41", "author": "Pfaller", "year": "1997", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "3623", "DOI": "10.1128/JCM.41.8.3623-3626.2003", "article-title": "Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi", "volume": "41", "author": "Diekema", "year": "2003", "journal-title": "J Clin Microbiol"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "769", "DOI": "10.1093/jac/48.6.769", "article-title": "Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans", "volume": "48", "author": "Barchiesi", "year": "2001", "journal-title": "J Antimicrob Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "513", "DOI": "10.1128/AAC.01447-07", "article-title": "Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B", "volume": "52", "author": "Spreghini", "year": "2008", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "2009", "DOI": "10.1128/AAC.00163-06", "article-title": "In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts", "volume": "50", "author": "Sabatelli", "year": "2006", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "2587", "DOI": "10.1128/AAC.00829-05", "article-title": "Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection", "volume": "50", "author": "Cacciapuoti", "year": "2006", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "3457", "DOI": "10.1128/AAC.00595-07", "article-title": "Synergistic effect of posaconazole and caspofungin against clinical zygomycetes", "volume": "51", "author": "Guembe", "year": "2007", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "854", "DOI": "10.1093/jac/dkh434", "article-title": "Combinations of antifungal agents in therapy: what value are they?", "volume": "54", "author": "Cuenca-Estrella", "year": "2004", "journal-title": "J Antimicrob Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "1223", "DOI": "10.1592/phco.28.10.1223", "article-title": "Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome", "volume": "28", "author": "Krishna", "year": "2008", "journal-title": "Pharmacotherapy"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "211", "DOI": "10.2165/00003088-200544020-00006", "article-title": "Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations", "volume": "44", "author": "Ezzet", "year": "2005", "journal-title": "Clin Pharmacokinet"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "1441", "DOI": "10.1086/598327", "article-title": "Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents", "volume": "48", "author": "Bruggemann", "year": "2009", "journal-title": "Clin Infect Dis"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "703", "DOI": "10.1128/AAC.00663-08", "article-title": "Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects", "volume": "53", "author": "Conte", "year": "2008", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "745", "DOI": "10.1093/jac/dki288", "article-title": "Activity of posaconazole in the treatment of central nervous system fungal infections", "volume": "56", "author": "Pitisuttithum", "year": "2005", "journal-title": "J Antimicrob Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "1468", "DOI": "10.1093/jac/dkn409", "article-title": "Posaconazole concentrations in the central nervous system", "volume": "62", "author": "Ruping", "year": "2008", "journal-title": "J Antimicrob Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB26|cit26", "doi-asserted-by": "crossref", "first-page": "495", "DOI": "10.1128/AAC.00472-06", "article-title": "Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers", "volume": "51", "author": "Sansone-Parsons", "year": "2007", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "267", "DOI": "10.1124/dmd.32.2.267", "article-title": "Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)", "volume": "32", "author": "Ghosal", "year": "2004", "journal-title": "Drug Metab Dispos"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "3543", "DOI": "10.1128/AAC.48.9.3543-3551.2004", "article-title": "Disposition of posaconazole following single-dose oral administration in healthy subjects", "volume": "48", "author": "Krieter", "year": "2004", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB29|cit29", "doi-asserted-by": "crossref", "first-page": "812", "DOI": "10.1128/AAC.00454-06", "article-title": "Posaconazole plasma concentrations in juvenile patients with invasive fungal infection", "volume": "51", "author": "Krishna", "year": "2007", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "185", "DOI": "10.1177/0091270004271402", "article-title": "Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease", "volume": "45", "author": "Courtney", "year": "2005", "journal-title": "J Clin Pharmacol"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "1386", "DOI": "10.1093/jac/dkn401", "article-title": "Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment", "volume": "62", "author": "Hachem", "year": "2008", "journal-title": "J Antimicrob Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "24", "DOI": "10.1128/AAC.00705-08", "article-title": "Antifungal therapeutic drug monitoring: established and emerging indications", "volume": "53", "author": "Andes", "year": "2009", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB33|cit33", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1185/03007990903364657", "article-title": "Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment", "volume": "26", "author": "Moton", "year": "2009", "journal-title": "Curr Med Res Opin"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB34|cit34", "doi-asserted-by": "crossref", "first-page": "1383", "DOI": "10.1086/516353", "article-title": "Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases", "volume": "26", "author": "Walsh", "year": "1998", "journal-title": "Clin Infect Dis"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB35|cit35", "doi-asserted-by": "crossref", "first-page": "301", "DOI": "10.1111/j.1365-2710.2009.01055.x", "article-title": "Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers", "volume": "34", "author": "Moton", "year": "2009", "journal-title": "J Clin Pharm Ther"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB36|cit36", "doi-asserted-by": "crossref", "first-page": "658", "DOI": "10.1128/AAC.50.2.658-666.2006", "article-title": "Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection", "volume": "50", "author": "Ullmann", "year": "2006", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB37|cit37", "doi-asserted-by": "crossref", "first-page": "2", "DOI": "10.1086/508774", "article-title": "Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial", "volume": "44", "author": "Walsh", "year": "2007", "journal-title": "Clin Infect Dis"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB38|cit38", "doi-asserted-by": "crossref", "first-page": "563", "DOI": "10.1086/324620", "article-title": "Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis", "volume": "34", "author": "Denning", "year": "2002", "journal-title": "Clin Infect Dis"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB39|cit39", "doi-asserted-by": "crossref", "first-page": "196", "DOI": "10.1016/j.jinf.2004.05.011", "article-title": "Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study", "volume": "50", "author": "Kartsonis", "year": "2005", "journal-title": "J Infect"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB40|cit40", "doi-asserted-by": "crossref", "first-page": "335", "DOI": "10.1056/NEJMoa061098", "article-title": "Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease", "volume": "356", "author": "Ullmann", "year": "2007", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB41|cit41", "doi-asserted-by": "crossref", "first-page": "1626", "DOI": "10.1086/587177", "article-title": "Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death", "volume": "46", "author": "Cornely", "year": "2008", "journal-title": "Clin Infect Dis"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB42|cit42", "doi-asserted-by": "crossref", "first-page": "348", "DOI": "10.1056/NEJMoa061094", "article-title": "Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia", "volume": "356", "author": "Cornely", "year": "2007", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB43|cit43", "doi-asserted-by": "crossref", "first-page": "e61", "DOI": "10.1086/500212", "article-title": "Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases", "volume": "42", "author": "Van Burik", "year": "2006", "journal-title": "Clin Infect Dis"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB44|cit44", "doi-asserted-by": "crossref", "first-page": "1179", "DOI": "10.1086/501457", "article-title": "A multicenter, randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS", "volume": "42", "author": "Vazquez", "year": "2006", "journal-title": "Clin Infect Dis"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB45|cit45", "doi-asserted-by": "crossref", "first-page": "607", "DOI": "10.1086/511039", "article-title": "Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection", "volume": "44", "author": "Skiest", "year": "2007", "journal-title": "Clin Infect Dis"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB46|cit46", "author": "Groll", "first-page": "52", "year": "2009", "article-title": "Slavage treatment with posaconazole in pediatric patients", "journal-title": "Mycoses"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB47|cit47", "doi-asserted-by": "crossref", "first-page": "1726", "DOI": "10.1086/504328", "article-title": "Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections", "volume": "42", "author": "Raad", "year": "2006", "journal-title": "Clin Infect Dis"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB48|cit48", "doi-asserted-by": "crossref", "first-page": "804", "DOI": "10.1128/AAC.48.3.804-808.2004", "article-title": "Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men", "volume": "48", "author": "Courtney", "year": "2004", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB49|cit49", "unstructured": "Courtney R Wexler D Statkevich P Lim J Batra V Laughlin M Effect of cimetidine on the pharmacokinetics of posaconazole in healthy volunteers"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB50|cit50", "doi-asserted-by": "crossref", "first-page": "958", "DOI": "10.1128/AAC.01034-08", "article-title": "The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers", "volume": "53", "author": "Krishna", "year": "2009", "journal-title": "Antimicrob Agents Chemother"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB51|cit51", "doi-asserted-by": "crossref", "first-page": "839", "DOI": "10.1086/597110", "article-title": "Omeprazole significantly reduces posaconazole serum trough level", "volume": "48", "author": "Alffenaar", "year": "2009", "journal-title": "Clin Infect Dis"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB52|cit52", "doi-asserted-by": "crossref", "first-page": "645", "DOI": "10.1016/j.ejps.2004.01.005", "article-title": "Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study", "volume": "21", "author": "Wexler", "year": "2004", "journal-title": "Eur J Pharm Sci"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB53|cit53", "doi-asserted-by": "crossref", "first-page": "685", "DOI": "10.2174/138920007782109805", "article-title": "Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs", "volume": "8", "author": "Galetin", "year": "2007", "journal-title": "Curr Drug Metab"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB54|cit54", "doi-asserted-by": "crossref", "first-page": "286", "DOI": "10.1016/j.clinthera.2009.02.022", "article-title": "Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers", "volume": "31", "author": "Krishna", "year": "2009", "journal-title": "Clin Ther"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB55|cit55", "doi-asserted-by": "crossref", "first-page": "298", "DOI": "10.1038/sj.clpt.6100054", "article-title": "Drug interaction studies: study design, data analysis, and implications for dosing and labeling", "volume": "81", "author": "Huang", "year": "2007", "journal-title": "Clin Pharmacol Ther"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB56|cit56", "author": "Merck & Co., Inc", "year": "2005", "volume-title": "Zocor\u00ae (Simvastatin) Tablets"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB57|cit57", "doi-asserted-by": "crossref", "first-page": "825", "DOI": "10.1592/phco.27.6.825", "article-title": "Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus", "volume": "27", "author": "Sansone-Parsons", "year": "2007", "journal-title": "Pharmacotherapy"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB58|cit58", "doi-asserted-by": "crossref", "first-page": "701", "DOI": "10.1185/03007990802644209", "article-title": "Effects of oral posaconazole on the pharmacokinetics of sirolimus", "volume": "25", "author": "Moton", "year": "2009", "journal-title": "Curr Med Res Opin"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB59|cit59", "author": "Drew", "first-page": "34", "year": "2006", "article-title": "Posaconazole in the treatment of selected IFIs", "journal-title": "Hospital Pharmacy"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB60|cit60", "author": "SP Europe", "year": "2007", "volume-title": "Noxafil 40\u2003mg/Ml Oral Suspension"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB61|cit61", "doi-asserted-by": "crossref", "first-page": "603", "DOI": "10.1007/s00134-008-1383-2", "article-title": "Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU", "volume": "35", "author": "Spriet", "year": "2009", "journal-title": "Intensive Care Med"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB62|cit62", "doi-asserted-by": "crossref", "first-page": "1415", "DOI": "10.1185/030079907X187937", "article-title": "Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men", "volume": "23", "author": "Krishma", "year": "2007", "journal-title": "Curr Med Res Opin"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB63|cit63", "doi-asserted-by": "crossref", "first-page": "545", "DOI": "10.1185/030079906X167507", "article-title": "Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men", "volume": "23", "author": "Krishna", "year": "2007", "journal-title": "Curr Med Res Opin"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB64|cit64", "doi-asserted-by": "crossref", "first-page": "876", "DOI": "10.1007/s00134-003-1715-1", "article-title": "Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of \u2018The Tarragona Strategy\u2019", "volume": "29", "author": "Sandiumenge", "year": "2003", "journal-title": "Intensive Care Med"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB65|cit65", "doi-asserted-by": "crossref", "first-page": "503", "DOI": "10.1086/590004", "article-title": "Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis", "volume": "47", "author": "Chamilos", "year": "2008", "journal-title": "Clin Infect Dis"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB66|cit66", "doi-asserted-by": "crossref", "first-page": "451", "DOI": "10.1038/sj.bmt.1705754", "article-title": "Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole", "volume": "40", "author": "Trifilio", "year": "2007", "journal-title": "Bone Marrow Transplant"}, {"key": "10.1111/j.1365-2125.2010.03680.x-BIB67|cit67", "doi-asserted-by": "crossref", "first-page": "235", "DOI": "10.1093/jac/dkm476", "article-title": "Tissue concentrations: do we ever learn?", "volume": "61", "author": "Mouton", "year": "2008", "journal-title": "J Antimicrob Chemother"}], "container-title": ["British Journal of Clinical Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2125.2010.03680.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 27]], "date-time": "2019-02-27T22:46:46Z", "timestamp": 1551307606000}, "score": 26.74643, "subtitle": ["Pharmacodynamics and pharmacokinetics of the antifungal posaconazole"], "issued": {"date-parts": [[2010, 9, 14]]}, "references-count": 67, "journal-issue": {"published-print": {"date-parts": [[2010, 10]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.1111/j.1365-2125.2010.03680.x", "relation": {"cites": []}, "ISSN": ["0306-5251"], "issn-type": [{"value": "0306-5251", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T15:44:37Z", "timestamp": 1574178277625}, "reference-count": 72, "publisher": "Springer Science and Business Media LLC", "issue": "13", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Pharmacokinetics"], "published-print": {"date-parts": [[2002]]}, "DOI": "10.2165/00003088-200241130-00004", "type": "journal-article", "created": {"date-parts": [[2006, 1, 19]], "date-time": "2006-01-19T11:54:35Z", "timestamp": 1137671675000}, "page": "1059-1076", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Pharmacokinetics and Pharmacodynamics of Rapacuronium Bromide"], "prefix": "10.1007", "volume": "41", "author": [{"given": "William J.", "family": "Wight", "sequence": "first", "affiliation": []}, {"given": "Peter M.C.", "family": "Wright", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "R1-4", "author": "Wierda", "volume": "41", "first-page": "213", "year": "1994", "journal-title": "Can J Anaesth", "DOI": "10.1007/BF03009833", "doi-asserted-by": "crossref"}, {"key": "R2-4", "author": "Bowman", "volume": "69", "first-page": "57", "year": "1988", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-198807000-00009", "doi-asserted-by": "crossref"}, {"key": "R3-4", "author": "Wierda", "volume": "11", "first-page": "45", "year": "1995", "journal-title": "Eur J Anaesthesiol Suppl"}, {"key": "R4-4", "author": "Wright", "volume": "90", "first-page": "16", "year": "1999", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199901000-00005", "doi-asserted-by": "crossref"}, {"key": "R5-4", "author": "Zhou", "volume": "85", "first-page": "246", "year": "2000", "journal-title": "Br J Anaesth", "DOI": "10.1093/bja/85.2.246", "doi-asserted-by": "crossref"}, {"key": "R6-4", "author": "Miguel", "volume": "91", "first-page": "1648", "year": "1999", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199912000-00016", "doi-asserted-by": "crossref"}, {"key": "R7-4", "author": "Schiere", "volume": "44", "first-page": "1138", "year": "1997", "journal-title": "naesth"}, {"key": "R8-4", "author": "Debaene", "volume": "86", "first-page": "1300", "year": "1997", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199706000-00011", "doi-asserted-by": "crossref"}, {"key": "R9-4", "author": "Kahwaji", "volume": "84", "first-page": "1011", "year": "1997", "journal-title": "Anesth Analg", "DOI": "10.1213/00000539-199705000-00011", "doi-asserted-by": "crossref"}, {"key": "R10-4", "author": "Wierda", "volume": "77", "first-page": "579", "year": "1993", "journal-title": "Anesth Analg", "DOI": "10.1213/00000539-199309000-00026", "doi-asserted-by": "crossref"}, {"key": "R11-4", "author": "Lichtor", "volume": "85", "first-page": "A805", "year": "1996", "journal-title": "Anesthesiology"}, {"key": "R12-4", "author": "Witkowski", "volume": "89", "first-page": "A978", "year": "1998", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199809170-00007", "doi-asserted-by": "crossref"}, {"key": "R13-4", "author": "Abboud", "volume": "87", "first-page": "A906", "year": "1997", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199709001-00906", "doi-asserted-by": "crossref"}, {"key": "R14-4", "author": "Hayes", "volume": "55", "first-page": "859", "year": "2000", "journal-title": "Anaesthesia", "DOI": "10.1046/j.1365-2044.2000.01541.x", "doi-asserted-by": "crossref"}, {"key": "R15-4", "author": "Abouleish", "volume": "83", "first-page": "862", "year": "1999", "journal-title": "Br J Anaesth", "DOI": "10.1093/bja/83.6.862", "doi-asserted-by": "crossref"}, {"key": "R16-4", "author": "Kopman", "volume": "93", "first-page": "1017", "year": "2000", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-200010000-00025", "doi-asserted-by": "crossref"}, {"key": "R17-4", "author": "Bevan", "volume": "9", "first-page": "36S", "year": "1997", "journal-title": "J Clin Anesth", "DOI": "10.1016/S0952-8180(97)00120-7", "doi-asserted-by": "crossref"}, {"key": "R18-4", "author": "Belmont", "volume": "82", "first-page": "1139", "year": "1995", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199505000-00008", "doi-asserted-by": "crossref"}, {"key": "R19-4", "author": "Savarese", "volume": "68", "first-page": "723", "year": "1988", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-198805000-00010", "doi-asserted-by": "crossref"}, {"key": "R20-4", "author": "Schiere", "volume": "88", "first-page": "640", "year": "1999", "journal-title": "Anesth Analg", "DOI": "10.1213/00000539-199903000-00032", "doi-asserted-by": "crossref"}, {"key": "R21-4", "author": "Lee", "volume": "86", "first-page": "48", "year": "1997", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199701000-00008", "doi-asserted-by": "crossref"}, {"key": "R22-4", "author": "Zhou", "volume": "91", "first-page": "596", "year": "2000", "journal-title": "Anesth Analg", "DOI": "10.1213/00000539-200009000-00018", "doi-asserted-by": "crossref"}, {"key": "R23-4", "author": "Zhou", "volume": "90", "first-page": "689", "year": "2000", "journal-title": "Anesth Analg", "DOI": "10.1097/00000539-200003000-00033", "doi-asserted-by": "crossref"}, {"key": "R24-4", "author": "Caldwell", "volume": "270", "first-page": "1216", "year": "1994", "journal-title": "J Pharmacol Exp Ther"}, {"key": "R25-4", "author": "Fisher", "volume": "93", "first-page": "1384", "year": "2000", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-200012000-00007", "doi-asserted-by": "crossref"}, {"key": "R26-4", "author": "Blobner", "volume": "85", "first-page": "724", "year": "2000", "journal-title": "Br J Anaesth", "DOI": "10.1093/bja/85.5.724", "doi-asserted-by": "crossref"}, {"key": "R27-4", "author": "Sparr", "volume": "82", "first-page": "537", "year": "1999", "journal-title": "Br J Anaesth", "DOI": "10.1093/bja/82.4.537", "doi-asserted-by": "crossref"}, {"key": "R28-4", "author": "Fleming", "volume": "91", "first-page": "1311", "year": "1999", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199911000-00023", "doi-asserted-by": "crossref"}, {"key": "R29-4", "author": "Viby-Mogensen", "volume": "40", "first-page": "59", "year": "1996", "journal-title": "Acta Anaesthesiol Scand", "DOI": "10.1111/j.1399-6576.1996.tb04389.x", "doi-asserted-by": "crossref"}, {"key": "R30-4", "author": "Onrust", "volume": "58", "first-page": "887", "year": "1999", "journal-title": "Drugs", "DOI": "10.2165/00003495-199958050-00011", "doi-asserted-by": "crossref"}, {"key": "R31-4", "author": "Meakin", "volume": "94", "first-page": "926", "year": "2001", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-200105000-00035", "doi-asserted-by": "crossref"}, {"key": "R32-4", "author": "Naguib", "volume": "94", "first-page": "924", "year": "2001", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-200105000-00034", "doi-asserted-by": "crossref"}, {"key": "R33-4", "author": "Kron", "volume": "94", "first-page": "923", "year": "2001", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-200105000-00033", "doi-asserted-by": "crossref"}, {"key": "R34-4", "author": "Goudsouzian", "volume": "94", "first-page": "727", "year": "2001", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-200105000-00006", "doi-asserted-by": "crossref"}, {"key": "R35-4", "author": "Purdy", "volume": "91", "first-page": "51", "year": "1999", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199907000-00011", "doi-asserted-by": "crossref"}, {"key": "R36-4", "author": "Mills", "volume": "83", "first-page": "727", "year": "1999", "journal-title": "Br J Anaesth", "DOI": "10.1093/bja/83.5.727", "doi-asserted-by": "crossref"}, {"key": "R37-4", "author": "Connolly", "volume": "74", "first-page": "473P", "year": "1995", "journal-title": "Br J Anaesth", "DOI": "10.1093/bja/74.2.229", "doi-asserted-by": "crossref"}, {"key": "R38-4", "author": "Baurain", "volume": "40", "first-page": "574", "year": "1996", "journal-title": "Acta Anaesthesiol Scand", "DOI": "10.1111/j.1399-6576.1996.tb04490.x", "doi-asserted-by": "crossref"}, {"key": "R39-4", "author": "Bevan", "volume": "90", "first-page": "S7", "year": "2000", "journal-title": "Anesth Analg", "DOI": "10.1097/00000539-200005001-00003", "doi-asserted-by": "crossref"}, {"key": "R40-4", "author": "Eriksson", "volume": "87", "first-page": "1035", "year": "1997", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199711000-00005", "doi-asserted-by": "crossref"}, {"key": "R41-4", "author": "Bevan", "volume": "89", "first-page": "333", "year": "1999", "journal-title": "Anesth Analg"}, {"key": "R42-4", "author": "McCourt", "volume": "82", "first-page": "755", "year": "1999", "journal-title": "Br J Anaesth", "DOI": "10.1093/bja/82.5.755", "doi-asserted-by": "crossref"}, {"key": "R43-4", "author": "Szenohradszky", "volume": "90", "first-page": "24", "year": "1999", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199901000-00006", "doi-asserted-by": "crossref"}, {"key": "R44-4", "author": "Duvaldestin", "volume": "91", "first-page": "1305", "year": "1999", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199911000-00022", "doi-asserted-by": "crossref"}, {"key": "R45-4", "author": "Kaplan", "volume": "89", "first-page": "1172", "year": "1999", "journal-title": "Anesth Analg", "DOI": "10.1213/00000539-199911000-00016", "doi-asserted-by": "crossref"}, {"key": "R46-4", "author": "Reynolds", "volume": "91", "first-page": "1285", "year": "1999", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199911000-00019", "doi-asserted-by": "crossref"}, {"key": "R47-4", "author": "Meakin", "volume": "92", "first-page": "1002", "year": "2000", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-200004000-00017", "doi-asserted-by": "crossref"}, {"key": "R48-4", "author": "Brandom", "volume": "47", "first-page": "143", "year": "2000", "journal-title": "Can J Anaesth", "DOI": "10.1007/BF03018850", "doi-asserted-by": "crossref"}, {"key": "R49-4", "author": "Denman", "volume": "94", "first-page": "3", "year": "2001", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-200101000-00006", "doi-asserted-by": "crossref"}, {"key": "R50-4", "author": "Levy", "volume": "89", "first-page": "290", "year": "1999", "journal-title": "Anesth Analg"}, {"key": "R51-4", "author": "Naguib", "volume": "75", "first-page": "588", "year": "1995", "journal-title": "Br J Anaesth", "DOI": "10.1093/bja/75.5.588", "doi-asserted-by": "crossref"}, {"key": "R52-4", "author": "Cannon", "volume": "35", "first-page": "350", "year": "1988", "journal-title": "Can J Anaesth", "DOI": "10.1007/BF03010854", "doi-asserted-by": "crossref"}, {"key": "R53-4", "author": "Witkowski", "volume": "87", "first-page": "A865", "year": "1997", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199709001-00865", "doi-asserted-by": "crossref"}, {"key": "R54-4", "author": "Bikhazi", "volume": "82", "first-page": "S29", "year": "1996", "journal-title": "Anesth Analg"}, {"key": "R55-4", "author": "Osmer", "volume": "15", "first-page": "585", "year": "1998", "journal-title": "Eur J Anaesthesiol", "DOI": "10.1097/00003643-199809000-00012", "doi-asserted-by": "crossref"}, {"key": "R56-4", "author": "Miguel", "volume": "87", "first-page": "A847", "year": "1997", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199709001-00847", "doi-asserted-by": "crossref"}, {"key": "R57-4", "author": "van den Broek", "volume": "73", "first-page": "331", "year": "1994", "journal-title": "Br J Anaesth", "DOI": "10.1093/bja/73.3.331", "doi-asserted-by": "crossref"}, {"key": "R58-4", "author": "Fisher", "volume": "90", "first-page": "993", "year": "1999", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199904000-00011", "doi-asserted-by": "crossref"}, {"key": "R59-4", "author": "Reynolds", "volume": "85", "first-page": "231", "year": "1996", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199608000-00002", "doi-asserted-by": "crossref"}, {"key": "R60-4", "author": "Reynolds", "volume": "92", "first-page": "376", "year": "2000", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-200002000-00018", "doi-asserted-by": "crossref"}, {"key": "R61-4", "author": "Wright", "volume": "80", "first-page": "488", "year": "1998", "journal-title": "Br J Anaesth", "DOI": "10.1093/bja/80.4.488", "doi-asserted-by": "crossref"}, {"key": "R62-4", "author": "Fisher", "volume": "37", "first-page": "402", "year": "1985", "journal-title": "Clin Pharmacol Ther", "DOI": "10.1038/clpt.1985.62", "doi-asserted-by": "crossref"}, {"key": "R63-4", "author": "Reynolds", "volume": "87", "first-page": "1096", "year": "1997", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199711000-00014", "doi-asserted-by": "crossref"}, {"key": "R64-4", "author": "Plaud", "volume": "86", "first-page": "48", "year": "1997", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199701000-00008", "doi-asserted-by": "crossref"}, {"key": "R65-4", "author": "Fisher", "volume": "86", "first-page": "558", "year": "1997", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199703000-00007", "doi-asserted-by": "crossref"}, {"key": "R66-4", "author": "Farenc", "volume": "58", "first-page": "185", "year": "1995", "journal-title": "Clin Pharmacol Ther", "DOI": "10.1016/0009-9236(95)90196-5", "doi-asserted-by": "crossref"}, {"key": "R67-4", "author": "Sorooshian", "volume": "85", "first-page": "1290", "year": "1996", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199612000-00010", "doi-asserted-by": "crossref"}, {"key": "R68-4", "author": "Donati", "volume": "73", "first-page": "870", "year": "1990", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199011000-00013", "doi-asserted-by": "crossref"}, {"key": "R69-4", "author": "Meistelman", "volume": "73", "first-page": "278", "year": "1991", "journal-title": "Anesth Analg", "DOI": "10.1213/00000539-199109000-00009", "doi-asserted-by": "crossref"}, {"key": "R70-4", "author": "Plaud", "volume": "85", "first-page": "77", "year": "1996", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199607000-00011", "doi-asserted-by": "crossref"}, {"key": "R71-4", "author": "Kopman", "volume": "91", "first-page": "1554", "year": "1999", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199911000-00057", "doi-asserted-by": "crossref"}, {"key": "R73-4", "author": "Fisher", "volume": "91", "first-page": "1555", "year": "1999", "journal-title": "Anesthesiology", "DOI": "10.1097/00000542-199911000-00059", "doi-asserted-by": "crossref"}], "container-title": ["Clinical Pharmacokinetics"], "language": "en", "deposited": {"date-parts": [[2019, 3, 21]], "date-time": "2019-03-21T12:53:32Z", "timestamp": 1553172812000}, "score": 26.256765, "subtitle": [""], "issued": {"date-parts": [[2002]]}, "references-count": 72, "journal-issue": {"issue": "13"}, "URL": "http://dx.doi.org/10.2165/00003088-200241130-00004", "relation": {"cites": []}, "ISSN": ["0312-5963"], "issn-type": [{"value": "0312-5963", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T15:44:21Z", "timestamp": 1574178261955}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "5", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Pharmacokinetics"], "published-print": {"date-parts": [[1998]]}, "DOI": "10.2165/00003088-199834050-00002", "type": "journal-article", "created": {"date-parts": [[2006, 1, 19]], "date-time": "2006-01-19T10:29:36Z", "timestamp": 1137666576000}, "page": "347-358", "source": "Crossref", "is-referenced-by-count": 61, "title": ["Pharmacokinetics and Pharmacodynamics of Hydroxyurea"], "prefix": "10.1007", "volume": "34", "author": [{"given": "Peter R.", "family": "Gwilt", "sequence": "first", "affiliation": []}, {"given": "William G.", "family": "Tracewell", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["Clinical Pharmacokinetics"], "language": "en", "deposited": {"date-parts": [[2013, 1, 20]], "date-time": "2013-01-20T14:24:24Z", "timestamp": 1358691864000}, "score": 26.256765, "subtitle": [""], "issued": {"date-parts": [[1998]]}, "references-count": 0, "journal-issue": {"issue": "5"}, "URL": "http://dx.doi.org/10.2165/00003088-199834050-00002", "ISSN": ["0312-5963"], "issn-type": [{"value": "0312-5963", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T05:35:08Z", "timestamp": 1574487308372}, "reference-count": 67, "publisher": "MDPI AG", "issue": "1", "license": [{"URL": "https://creativecommons.org/licenses/by/4.0/", "start": {"date-parts": [[2011, 1, 4]], "date-time": "2011-01-04T00:00:00Z", "timestamp": 1294099200000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Pharmaceutics"], "DOI": "10.3390/pharmaceutics3010012", "type": "journal-article", "created": {"date-parts": [[2011, 1, 4]], "date-time": "2011-01-04T16:46:30Z", "timestamp": 1294159590000}, "page": "12-33", "source": "Crossref", "is-referenced-by-count": 87, "title": ["The Pharmacokinetics and Pharmacodynamics of Iron Preparations"], "prefix": "10.3390", "volume": "3", "author": [{"given": "Peter", "family": "Geisser", "sequence": "first", "affiliation": []}, {"given": "Susanna", "family": "Burckhardt", "sequence": "additional", "affiliation": []}], "member": "1968", "published-online": {"date-parts": [[2011, 1, 4]]}, "reference": [{"key": "ref1", "first-page": "161", "article-title": "Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron", "volume": "19", "author": "Gotloib", "year": "2006", "journal-title": "J. Nephrol."}, {"key": "ref2", "doi-asserted-by": "crossref", "first-page": "2485", "DOI": "10.1016/j.jacc.2006.08.034", "article-title": "Etiology of anemia in patients with advanced heart failure", "volume": "48", "author": "Nanas", "year": "2006", "journal-title": "J. Amer. Coll. Cardiol."}, {"key": "ref3", "doi-asserted-by": "crossref", "first-page": "1190", "DOI": "10.1136/gut.2003.035758", "article-title": "Iron, anaemia, and inflammatory bowel diseases", "volume": "53", "author": "Gasche", "year": "2004", "journal-title": "Gut"}, {"key": "ref4", "doi-asserted-by": "crossref", "first-page": "143", "DOI": "10.1053/j.ackd.2008.12.008", "article-title": "Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?", "volume": "16", "author": "Kalantar-Zadeh", "year": "2009", "journal-title": "Adv. Chronic Kidney Dis."}, {"key": "ref5", "first-page": "369", "article-title": "Bioavailability of oral vitamins, minerals, and trace elements in perspective", "volume": "47", "author": "Sch\u00fcmann", "year": "1997", "journal-title": "Drug Res."}, {"key": "ref6", "doi-asserted-by": "crossref", "first-page": "1986", "DOI": "10.1056/NEJM199912233412607", "article-title": "Disorders of iron metabolism", "volume": "341", "author": "Andrews", "year": "1999", "journal-title": "N. Engl. J. Med."}, {"key": "ref7", "author": "Crichton", "year": "2008", "series-title": "Iron Therapy with Special Emphasis on Intravenous Administration"}, {"key": "ref8", "unstructured": "Committee for Proprietary Medicinal Products (CPMP)http://faculty.ksu.edu.sa/64448/Documents/EMEA%20Guideline%20BE.pdf"}, {"key": "ref9", "doi-asserted-by": "crossref", "first-page": "51", "DOI": "10.1007/s003940050046", "article-title": "The concept of iron and its bioavailability", "volume": "38", "author": "Wienk", "year": "1999", "journal-title": "Eur. J. Nutr."}, {"key": "ref10", "doi-asserted-by": "crossref", "first-page": "296", "DOI": "10.1046/j.1365-2141.1999.01179.x", "article-title": "Pharmacokinetics and red cell utilization of iron(III)-hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography", "volume": "104", "author": "Beshara", "year": "1999", "journal-title": "Br. J. Haematol."}, {"key": "ref11", "author": "Forth", "first-page": "36", "year": "1992", "series-title": "Iron: Bioavailability, Absorption, Utilization"}, {"key": "ref12", "author": "Ekenved", "year": "1976", "series-title": "Iron Absorption Studies"}, {"key": "ref13", "first-page": "3", "article-title": "True iron bioavailability, iron pharmacokinetics and clinically silent side effects", "volume": "1", "author": "Geisser", "year": "2009", "journal-title": "Nutr. Immun. Health"}, {"key": "ref14", "first-page": "S93", "article-title": "Structure, chemistry, and pharmacokinetics of intravenous iron agents", "volume": "15", "author": "Danielson", "year": "2004", "journal-title": "Am. Soc. Nephrol."}, {"key": "ref15", "doi-asserted-by": "crossref", "first-page": "57", "DOI": "10.1007/s00775-007-0297-8", "article-title": "Nature of non-transferrin-bound iron: studies on iron citrate complexes and the thalassemic sera", "volume": "13", "author": "Evans", "year": "2008", "journal-title": "J. Biol. Inorg. Chem."}, {"key": "ref16", "doi-asserted-by": "crossref", "first-page": "1103", "DOI": "10.1016/j.ajkd.2003.08.008", "article-title": "Reactivity of iron compounds (letter)", "volume": "42", "author": "Geisser", "year": "2003", "journal-title": "Am. J. Kidney Dis."}, {"key": "ref17", "first-page": "1439", "article-title": "Structure/histotoxicity relationship of parenteral iron preparations", "volume": "42", "author": "Geisser", "year": "1992", "journal-title": "Drug Res."}, {"key": "ref18", "doi-asserted-by": "crossref", "first-page": "561", "DOI": "10.1093/ndt/gfg579", "article-title": "Labile iron in parenteral iron formulations: a quantitative and comparative study", "volume": "19", "author": "Van Wyck", "year": "2004", "journal-title": "Nephrol. Dialysis Transplant."}, {"key": "ref19", "doi-asserted-by": "crossref", "first-page": "988", "DOI": "10.1053/ajkd.2001.28587", "article-title": "Intravenous iron sucrose: establishing a safe dose", "volume": "38", "author": "Chandler", "year": "2001", "journal-title": "Am. J. Kidney Dis."}, {"key": "ref20", "first-page": "615", "article-title": "Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers", "volume": "46", "author": "Danielson", "year": "1996", "journal-title": "Drug Res."}, {"key": "ref21", "doi-asserted-by": "crossref", "first-page": "574", "DOI": "10.1592/phco.24.6.574.34750", "article-title": "Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects", "volume": "24", "author": "Seligman", "year": "2004", "journal-title": "Pharmacotherapy"}, {"key": "ref22", "first-page": "362", "article-title": "Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia", "volume": "60", "author": "Geisser", "year": "2010", "journal-title": "Drug Res."}, {"key": "ref23", "doi-asserted-by": "crossref", "first-page": "489", "DOI": "10.1111/j.1365-2362.2009.02130.x", "article-title": "Physico chemical properties of ferumoxytol, a new intravenous iron preparation", "volume": "39", "author": "Balakrishnan", "year": "2009", "journal-title": "Eur. J. Clin. Invest."}, {"key": "ref24", "first-page": "357", "article-title": "Characteristics of iron dextran utilization in man", "volume": "34", "author": "Henderson", "year": "1969", "journal-title": "Blood"}, {"key": "ref25", "doi-asserted-by": "crossref", "first-page": "400", "DOI": "10.1159/000087212", "article-title": "Pharmacokinetics study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients", "volume": "25", "author": "Landry", "year": "2005", "journal-title": "Am. J. Nephrol."}, {"key": "ref26", "first-page": "373", "article-title": "Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder", "volume": "60", "author": "Geisser", "year": "2010", "journal-title": "Drug Res."}, {"key": "ref27", "doi-asserted-by": "crossref", "first-page": "24", "DOI": "10.1016/j.cell.2010.06.028", "article-title": "Two to tango: regulation of Mammalian iron metabolism", "volume": "142", "author": "Hentze", "year": "2010", "journal-title": "Cell"}, {"key": "ref28", "doi-asserted-by": "crossref", "first-page": "6865", "DOI": "10.1016/j.febslet.2006.11.048", "article-title": "Haem carrier protein 1 (HCP1): Expression and functional studies in cultured cells", "volume": "580", "author": "Latunde-Dada", "year": "2006", "journal-title": "FEBS Lett."}, {"key": "ref29", "doi-asserted-by": "crossref", "first-page": "917", "DOI": "10.1016/j.cell.2006.09.041", "article-title": "Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption", "volume": "127", "author": "Qiu", "year": "2006", "journal-title": "Cell"}, {"key": "ref30", "doi-asserted-by": "crossref", "first-page": "469", "DOI": "10.1124/jpet.107.122606", "article-title": "Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter", "volume": "322", "author": "Nakai", "year": "2007", "journal-title": "J. Pharmacol. Exp. Ther."}, {"key": "ref31", "doi-asserted-by": "crossref", "first-page": "5", "DOI": "10.1016/j.cmet.2006.12.004", "article-title": "When is a heme transporter not a heme transporter? When it's a folate transporter", "volume": "5", "author": "Andrew", "year": "2007", "journal-title": "Cell Metab."}, {"key": "ref32", "doi-asserted-by": "crossref", "first-page": "152", "DOI": "10.1038/11072", "article-title": "Haem oxygenase-1 prevents cell death by regulating cellular iron", "volume": "1", "author": "Ferris", "year": "1999", "journal-title": "Nat. Cell. Biol."}, {"key": "ref33", "doi-asserted-by": "crossref", "first-page": "1301", "DOI": "10.1515/znb-1969-1018", "article-title": "Dose relationship of intestinal iron absorption in men with normal iron stores and persons with prelatent/latent iron deficiency", "volume": "24b", "author": "Heinrich", "year": "1969", "journal-title": "Z. Naturforshg"}, {"key": "ref34", "doi-asserted-by": "crossref", "first-page": "273", "DOI": "10.1007/s10534-007-9116-5", "article-title": "Non-transferrin-bound iron in plasma following administration of oral iron drugs", "volume": "21", "author": "Dresow", "year": "2008", "journal-title": "Biometals"}, {"key": "ref35", "doi-asserted-by": "crossref", "first-page": "782", "DOI": "10.1111/j.1365-2362.2004.01416.x", "article-title": "Oral ferrous sulphate leads to a marked increase in pro-oxidant nontransferrin-bound iron", "volume": "34", "author": "Hutchinson", "year": "2004", "journal-title": "Eur. J. Clin. Invest."}, {"key": "ref36", "doi-asserted-by": "crossref", "first-page": "S61", "DOI": "10.1046/j.1523-1755.1999.055Suppl.69061.x", "article-title": "Strategies for iron supplementation: oral versus intravenous", "volume": "69", "author": "Macdougall", "year": "1999", "journal-title": "Kidney Int. Suppl."}, {"key": "ref37", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1111/j.1600-0609.1976.tb00347.x", "article-title": "Serum iron increase as a measure of iron absorption -studies on the correlation with total absorption", "volume": "17", "author": "Ekenved", "year": "1976", "journal-title": "Scand. J. Haematol."}, {"key": "ref38", "first-page": "274", "article-title": "The regulation of iron absorption I. a search for humoral factors", "volume": "55", "author": "Beutler", "year": "1960", "journal-title": "J. Lab. Clin. Med."}, {"key": "ref39", "first-page": "116", "article-title": "Judgement of measured values of intestinal iron absorption", "volume": "37", "author": "Werner", "year": "1987", "journal-title": "Drug Res."}, {"key": "ref40", "doi-asserted-by": "crossref", "first-page": "1493", "DOI": "10.1007/BF01716100", "article-title": "Correlation of postaborptive serum iron increase and erythrocyte-59Fe-incorporation with the whole body retention of absorbed 59Fe", "volume": "60", "author": "Heinrich", "year": "1982", "journal-title": "Klin. Wochenschr."}, {"key": "ref41", "first-page": "122", "article-title": "Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations", "volume": "37", "author": "Kaltwasser", "year": "1987", "journal-title": "Drug Res."}, {"key": "ref42", "first-page": "392", "article-title": "Effect of oral aluminium hydroxide on iron absorption from iron(III)-hydroxide polymaltose complex in patients with iron deficiency anemia: A single-centre randomized controlled isotope study", "volume": "57", "author": "Potgieter", "year": "2007", "journal-title": "Drug Res."}, {"key": "ref43", "doi-asserted-by": "crossref", "first-page": "436", "DOI": "10.1111/j.1365-2362.1991.tb01392.x", "article-title": "Assessment of iron availability using stable 54Fe", "volume": "21", "author": "Kaltwasser", "year": "1991", "journal-title": "Eur. J. Clin. Invest."}, {"key": "ref44", "first-page": "100", "article-title": "Pharmacokinetics of iron salts and ferric hydroxide-carbohydrate complexes", "volume": "37", "author": "Geisser", "year": "1987", "journal-title": "Drug Res."}, {"key": "ref45", "first-page": "367", "article-title": "Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose", "volume": "15", "author": "Jacobs", "year": "1984", "journal-title": "J. Med."}, {"key": "ref46", "doi-asserted-by": "crossref", "first-page": "77", "DOI": "10.1080/10245332.2000.11746490", "article-title": "Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia", "volume": "5", "author": "Jacobs", "year": "2000", "journal-title": "Hematology"}, {"key": "ref47", "doi-asserted-by": "crossref", "first-page": "853", "DOI": "10.1046/j.1365-2141.2003.03590.x", "article-title": "Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography", "volume": "120", "author": "Beshara", "year": "2003", "journal-title": "Br. J. Haematol."}, {"key": "ref48", "first-page": "1065", "article-title": "Absorption of iron polymaltose and ferrous sulphate in rats and humans", "volume": "55", "author": "Jacobs", "year": "1979", "journal-title": "S. Afr. Med. J."}, {"key": "ref49", "doi-asserted-by": "crossref", "first-page": "445", "DOI": "10.1007/s002160050608", "article-title": "Stable isotope labels as a tool to determine the iron absorption by Peruvian school children from a breakfast meal", "volume": "359", "author": "Walczyk", "year": "1997", "journal-title": "Fresenius J. Anal. Chem."}, {"key": "ref50", "doi-asserted-by": "crossref", "first-page": "1868", "DOI": "10.1093/jn/136.7.1868", "article-title": "Erythrocyte iron incorporation but not absorption is increased by intravenous iron administration in erythropoietin-treated premature infants", "volume": "136", "author": "Widness", "year": "2006", "journal-title": "J. Nutr."}, {"key": "ref51", "doi-asserted-by": "crossref", "first-page": "3", "DOI": "10.1111/j.0954-6820.1960.tb15570.x", "article-title": "Iron absorption studies", "volume": "168", "author": "Hallberg", "year": "1960", "journal-title": "Acta Med. Scand."}, {"key": "ref52", "doi-asserted-by": "crossref", "first-page": "862", "DOI": "10.1118/1.596168", "article-title": "An iron metabolism study in humans by means of stable tracers", "volume": "15", "author": "Cantone", "year": "1988", "journal-title": "Med. Phys."}, {"key": "ref53", "doi-asserted-by": "crossref", "first-page": "349", "DOI": "10.1007/s00109-005-0029-x", "article-title": "Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy", "volume": "84", "author": "Oudit", "year": "2006", "journal-title": "J. Mol. Med."}, {"key": "ref54", "doi-asserted-by": "crossref", "first-page": "736", "DOI": "10.1053/j.ajkd.2007.03.007", "article-title": "Iron management in nondialysis-dependent CKD", "volume": "49", "author": "Fishbane", "year": "2007", "journal-title": "Am. J. Kidney Dis."}, {"key": "ref55", "doi-asserted-by": "crossref", "first-page": "498", "DOI": "10.1006/cimm.1994.1094", "article-title": "In vitro modulation of T-cell surface molecules by iron", "volume": "154", "author": "Santos", "year": "1994", "journal-title": "Cell. Immunol."}, {"key": "ref56", "doi-asserted-by": "crossref", "first-page": "317", "DOI": "10.1038/icb.1990.43", "article-title": "Clonal analysis of the effect of iron on human cytotoxic and proliferation T lymphocytes", "volume": "68", "author": "Rudd", "year": "1990", "journal-title": "Immunol. Cell. Biol."}, {"key": "ref57", "doi-asserted-by": "crossref", "first-page": "739", "DOI": "10.2165/00003495-200969060-00007", "article-title": "Ferric carboxymaltose: a review of its use in iron-deficiency anaemia", "volume": "69", "author": "Lyseng-Williamson", "year": "2009", "journal-title": "Drugs"}, {"key": "ref58", "doi-asserted-by": "crossref", "first-page": "2436", "DOI": "10.1056/NEJMoa0908355", "article-title": "Ferric carboxymaltose in patients with heart failure and iron deficiency", "volume": "361", "author": "Anker", "year": "2009", "journal-title": "N. Engl. J. Med."}, {"key": "ref59", "doi-asserted-by": "crossref", "first-page": "117", "DOI": "10.1053/j.ackd.2008.12.010", "article-title": "Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medication", "volume": "6", "author": "Macdougall", "year": "2009", "journal-title": "Adv. Chronic Kidney Dis."}, {"key": "ref60", "doi-asserted-by": "crossref", "first-page": "1443", "DOI": "10.1093/ndt/gfh820", "article-title": "Hypersensitivity reactions and deaths associated with intravenous iron preparations", "volume": "20", "author": "Bailie", "year": "2005", "journal-title": "Nephrol. Dialysis Transplant."}, {"key": "ref61", "doi-asserted-by": "crossref", "first-page": "378", "DOI": "10.1093/ndt/gfi253", "article-title": "Update on adverse drug events associated with parenteral iron", "volume": "21", "author": "Chertow", "year": "2006", "journal-title": "Nephrol. Dialysis Transplant."}, {"key": "ref62", "first-page": "315", "article-title": "FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease", "volume": "85", "author": "Lu", "year": "2010", "journal-title": "Am. J. Hematol."}, {"key": "ref63", "first-page": "341", "article-title": "Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol", "volume": "3", "author": "Santosh", "year": "2010", "journal-title": "Nephrol. Dialysis Transplant."}, {"key": "ref64", "first-page": "399", "article-title": "The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review", "volume": "60", "author": "Qunibi", "year": "2010", "journal-title": "Drug Res."}, {"key": "ref65", "doi-asserted-by": "crossref", "first-page": "543", "DOI": "10.1111/j.0954-6820.1972.tb04864.x", "article-title": "Availability of iron dextran for hemoglobin synthesis", "volume": "192", "author": "Olsson", "year": "1972", "journal-title": "Acta Med. Scand."}, {"key": "ref66", "doi-asserted-by": "crossref", "first-page": "1121", "DOI": "10.1016/S0271-5317(99)00073-1", "article-title": "Oral supplementation with ferrous sulphate but not with non-ionic iron polymaltose complex increases the susceptibility of plasma lipoproteins to oxidation", "volume": "19", "author": "Tuomainen", "year": "1999", "journal-title": "Nutr. Res."}, {"key": "ref67", "first-page": "439", "article-title": "Safety and efficacy of iron(III)-hydroxide polymaltose complex / a review of over 25 years experience", "volume": "57", "author": "Geisser", "year": "2007", "journal-title": "Drug Res."}], "container-title": ["Pharmaceutics"], "language": "en", "link": [{"URL": "http://www.mdpi.com/1999-4923/3/1/12/pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 7]], "date-time": "2019-06-07T15:04:15Z", "timestamp": 1559919855000}, "score": 24.908293, "issued": {"date-parts": [[2011, 1, 4]]}, "references-count": 67, "journal-issue": {"published-online": {"date-parts": [[2011, 3]]}, "issue": "1"}, "alternative-id": ["pharmaceutics3010012"], "URL": "http://dx.doi.org/10.3390/pharmaceutics3010012", "relation": {"cites": []}, "ISSN": ["1999-4923"], "issn-type": [{"value": "1999-4923", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T11:36:17Z", "timestamp": 1574336177626}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "6", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Pharmacokinetics"], "published-print": {"date-parts": [[1991, 6]]}, "DOI": "10.2165/00003088-199120060-00004", "type": "journal-article", "created": {"date-parts": [[2007, 12, 5]], "date-time": "2007-12-05T10:35:02Z", "timestamp": 1196850902000}, "page": "477-490", "source": "Crossref", "is-referenced-by-count": 97, "title": ["The Effects of Diabetes Mellitus on Pharmacokinetics and Pharmacodynamics in Humans"], "prefix": "10.1007", "volume": "20", "author": [{"given": "Peter R.", "family": "Gwilt", "sequence": "first", "affiliation": []}, {"given": "Ramez R.", "family": "Nahhas", "sequence": "additional", "affiliation": []}, {"given": "William G.", "family": "Tracewell", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["Clinical Pharmacokinetics"], "language": "en", "deposited": {"date-parts": [[2013, 1, 20]], "date-time": "2013-01-20T14:56:57Z", "timestamp": 1358693817000}, "score": 23.262854, "subtitle": [""], "issued": {"date-parts": [[1991, 6]]}, "references-count": 0, "journal-issue": {"issue": "6"}, "URL": "http://dx.doi.org/10.2165/00003088-199120060-00004", "ISSN": ["0312-5963"], "issn-type": [{"value": "0312-5963", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T05:21:06Z", "timestamp": 1574140866419}, "reference-count": 0, "publisher": "SAGE Publications", "issue": "11", "license": [{"URL": "http://journals.sagepub.com/page/policies/text-and-data-mining-license", "start": {"date-parts": [[2004, 11, 1]], "date-time": "2004-11-01T00:00:00Z", "timestamp": 1099267200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Ann Pharmacother"], "published-print": {"date-parts": [[2004, 11]]}, "DOI": "10.1345/aph.1e304", "type": "journal-article", "created": {"date-parts": [[2004, 10, 13]], "date-time": "2004-10-13T01:33:50Z", "timestamp": 1097631230000}, "page": "1973-1973", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Book Review: Handbook of Anticancer Pharmacokinetics and Pharmacodynamics"], "prefix": "10.1177", "volume": "38", "author": [{"given": "Peter R", "family": "Gwilt", "sequence": "first", "affiliation": [{"name": "Associate Professor of Pharmaceutical Sciences, Department of Pharmaceutical Sciences, College of Pharmacy University of Nebraska Medical Center, Omaha, Nebraska"}]}], "member": "179", "published-online": {"date-parts": [[2004, 11]]}, "container-title": ["Annals of Pharmacotherapy"], "language": "en", "link": [{"URL": "http://journals.sagepub.com/doi/pdf/10.1345/aph.1E304", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://journals.sagepub.com/doi/full-xml/10.1345/aph.1E304", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://journals.sagepub.com/doi/pdf/10.1345/aph.1E304", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 2, 14]], "date-time": "2019-02-14T12:06:58Z", "timestamp": 1550146018000}, "score": 22.926573, "issued": {"date-parts": [[2004, 11]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2004, 11]]}, "published-print": {"date-parts": [[2004, 11]]}, "issue": "11"}, "alternative-id": ["10.1345/aph.1E304"], "URL": "http://dx.doi.org/10.1345/aph.1e304", "ISSN": ["1060-0280", "1542-6270"], "issn-type": [{"value": "1060-0280", "type": "print"}, {"value": "1542-6270", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T07:11:25Z", "timestamp": 1574147485432}, "reference-count": 0, "publisher": "American Psychiatric Association Publishing", "issue": "1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["AJP"], "published-print": {"date-parts": [[2003, 1]]}, "DOI": "10.1176/appi.ajp.160.1.1", "type": "journal-article", "created": {"date-parts": [[2002, 12, 27]], "date-time": "2002-12-27T15:22:39Z", "timestamp": 1041002559000}, "page": "1-2", "source": "Crossref", "is-referenced-by-count": 71, "title": ["Predisposition to Addiction: Pharmacokinetics, Pharmacodynamics, and Brain Circuitry"], "prefix": "10.1176", "volume": "160", "author": [{"given": "Peter W.", "family": "Kalivas", "sequence": "first", "affiliation": []}], "member": "230", "container-title": ["American Journal of Psychiatry"], "language": "en", "deposited": {"date-parts": [[2014, 12, 17]], "date-time": "2014-12-17T21:18:43Z", "timestamp": 1418851123000}, "score": 22.926573, "issued": {"date-parts": [[2003, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2003, 1]]}, "issue": "1"}, "alternative-id": ["10.1176/appi.ajp.160.1.1"], "URL": "http://dx.doi.org/10.1176/appi.ajp.160.1.1", "ISSN": ["0002-953X", "1535-7228"], "issn-type": [{"value": "0002-953X", "type": "print"}, {"value": "1535-7228", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T11:46:37Z", "timestamp": 1574163997524}, "reference-count": 52, "publisher": "Wiley", "issue": "8", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 7548, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Chirality"], "published-print": {"date-parts": [[1995]]}, "DOI": "10.1002/chir.530070806", "type": "journal-article", "created": {"date-parts": [[2005, 1, 7]], "date-time": "2005-01-07T15:50:16Z", "timestamp": 1105113016000}, "page": "586-597", "source": "Crossref", "is-referenced-by-count": 39, "title": ["Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves"], "prefix": "10.1002", "volume": "7", "author": [{"given": "Maria Fabiana", "family": "Landoni", "sequence": "first", "affiliation": []}, {"given": "Peter", "family": "Lees", "sequence": "additional", "affiliation": []}], "member": "311", "reference": [{"key": "10.1002/chir.530070806-BIB1", "author": "Testa", "volume": "16", "first-page": "265", "year": "1986", "journal-title": "Xenobiotica"}, {"key": "10.1002/chir.530070806-BIB2", "author": "Caldwell", "volume": "37", "first-page": "105", "year": "1988", "journal-title": "Biochem. Pharmacol."}, {"key": "10.1002/chir.530070806-BIB3", "author": "Tucker", "volume": "45", "first-page": "309", "year": "1990", "journal-title": "Pharmacol. Ther."}, {"key": "10.1002/chir.530070806-BIB4", "author": "Suesa", "volume": "5", "first-page": "589", "year": "1993", "journal-title": "Chirality"}, {"key": "10.1002/chir.530070806-BIB5", "author": "Evans", "volume": "31", "first-page": "131", "year": "1991", "journal-title": "Br. J. Clin. Pharmacol.", "DOI": "10.1111/j.1365-2125.1991.tb05500.x", "doi-asserted-by": "crossref"}, {"key": "10.1002/chir.530070806-BIB6", "author": "Hayball", "volume": "4", "first-page": "484", "year": "1992", "journal-title": "Chirality"}, {"key": "10.1002/chir.530070806-BIB7", "author": "Higgins", "volume": "36", "first-page": "284", "year": "1984", "journal-title": "Res. Vet. Sci."}, {"key": "10.1002/chir.530070806-BIB8", "author": "Foster", "volume": "416", "first-page": "388", "year": "1987", "journal-title": "J. Chromatogr."}, {"key": "10.1002/chir.530070806-BIB9", "author": "Sedgwick", "volume": "18", "first-page": "429", "year": "1986", "journal-title": "Agents Actions"}, {"key": "10.1002/chir.530070806-BIB10", "author": "Fishman", "first-page": "929", "year": "1974", "unstructured": "?-Glucuronidase. In: Methods of Enzymatic Analysis. ed. New York: Academic Press, 1974: 929-943.", "volume-title": "Methods of Enzymatic Analysis", "DOI": "10.1016/B978-0-12-091302-2.50082-7", "doi-asserted-by": "crossref"}, {"key": "10.1002/chir.530070806-BIB11", "author": "Winstanley", "volume": "52", "first-page": "273", "year": "1992", "journal-title": "Res. Vet. Sci.", "DOI": "10.1016/0034-5288(92)90024-V", "doi-asserted-by": "crossref"}, {"key": "10.1002/chir.530070806-BIB12", "author": "Hansen", "volume": "119", "first-page": "203", "year": "1989", "journal-title": "J. Immunol. Methods"}, {"key": "10.1002/chir.530070806-BIB13", "author": "Flick", "volume": "68", "first-page": "167", "year": "1984", "journal-title": "J. Immunol. Methods"}, {"key": "10.1002/chir.530070806-BIB14", "author": "Helle", "volume": "18", "first-page": "1535", "year": "1988", "journal-title": "Eur. J. Immunol."}, {"key": "10.1002/chir.530070806-BIB15", "author": "Landoni", "volume": "18", "first-page": "315", "year": "1995", "journal-title": "J. Vet. Pharmacol. Ther."}, {"key": "10.1002/chir.530070806-BIB16", "author": "Akaike", "volume": "14", "first-page": "5", "year": "1976", "journal-title": "Math. Sci."}, {"key": "10.1002/chir.530070806-BIB17", "author": "Yamaoka", "volume": "6", "first-page": "165", "year": "1978", "journal-title": "J. Pharmacokin. Biopharm."}, {"key": "10.1002/chir.530070806-BIB18", "author": "Baggot", "volume": "1", "first-page": "111", "year": "1978", "journal-title": "J. Vet. Pharmacol. Ther."}, {"key": "10.1002/chir.530070806-BIB19", "author": "Gibaldi", "year": "1982", "unstructured": "Pharmacokinetics. ed. New York: Plenum Press, 1982.", "volume-title": "Pharmacokinetics"}, {"key": "10.1002/chir.530070806-BIB20", "author": "Dahlstrom", "volume": "6", "first-page": "41", "year": "1978", "journal-title": "J. Pharmacol. Biopharm."}, {"key": "10.1002/chir.530070806-BIB21", "author": "Fuseau", "volume": "35", "first-page": "733", "year": "1984", "journal-title": "Clin. Pharmacol. Ther.", "DOI": "10.1038/clpt.1984.104", "doi-asserted-by": "crossref"}, {"key": "10.1002/chir.530070806-BIB22", "author": "Holford", "volume": "6", "first-page": "429", "year": "1981", "journal-title": "Clin. Pharmacol. Kinet.", "DOI": "10.2165/00003088-198106060-00002", "doi-asserted-by": "crossref"}, {"key": "10.1002/chir.530070806-BIB23", "author": "Holford", "volume": "16", "first-page": "143", "year": "1982", "journal-title": "Pharmacol. Ther."}, {"key": "10.1002/chir.530070806-BIB24", "author": "Sheiner", "volume": "25", "first-page": "358", "year": "1979", "journal-title": "Clin. Pharmacol."}, {"key": "10.1002/chir.530070806-BIB25", "author": "Sheiner", "first-page": "139", "year": "1985", "unstructured": "Modeling pharmacodynamics: parametric and non-parametric approaches. In: Variability in Drug Therapy: Description, Estimation and Control. eds. New York: Raven Press, 1985: 139-152.", "volume-title": "Variability in Drug Therapy: Description, Estimation and Control"}, {"key": "10.1002/chir.530070806-BIB26", "author": "Foster", "volume": "77", "first-page": "70", "year": "1988", "journal-title": "J. Pharm. Sci."}, {"key": "10.1002/chir.530070806-BIB27", "author": "Foster", "volume": "78", "first-page": "881", "year": "1989", "journal-title": "J. Pharm. Sci."}, {"key": "10.1002/chir.530070806-BIB28", "author": "Sallustio", "volume": "26", "first-page": "765", "year": "1988", "journal-title": "Br. J. Clin. Pharmacol.", "DOI": "10.1111/j.1365-2125.1988.tb05317.x", "doi-asserted-by": "crossref"}, {"key": "10.1002/chir.530070806-BIB29", "author": "Mauleon", "volume": "6", "first-page": "537", "year": "1994", "journal-title": "Chirality"}, {"key": "10.1002/chir.530070806-BIB30", "author": "Foster", "volume": "16", "first-page": "623", "year": "1988", "journal-title": "Drug Metabol. Dispos."}, {"key": "10.1002/chir.530070806-BIB31", "author": "Iwakawa", "volume": "19", "first-page": "717", "year": "1991", "journal-title": "Drug Metabol. Dispos."}, {"key": "10.1002/chir.530070806-BIB32", "author": "Rossetti", "volume": "14", "first-page": "256", "year": "1986", "journal-title": "IRCS J. Med. Sci."}, {"key": "10.1002/chir.530070806-BIB33", "author": "Tamai", "volume": "7", "first-page": "29", "year": "1991", "journal-title": "Anal. Sci."}, {"key": "10.1002/chir.530070806-BIB34", "author": "Abas", "volume": "240", "first-page": "637", "year": "1987", "journal-title": "J. Pharmacol. Exp. Ther."}, {"key": "10.1002/chir.530070806-BIB35", "author": "Delatour", "volume": "177", "first-page": "515", "year": "1993", "journal-title": "Bull. Acad. Natl. Med."}, {"key": "10.1002/chir.530070806-BIB36", "author": "Jamali", "volume": "79", "first-page": "460", "year": "1990", "journal-title": "J. Pharm. Sci."}, {"key": "10.1002/chir.530070806-BIB37", "author": "Benoit", "year": "1993", "unstructured": "An in vivo-in vitro correlation in the chiral inversion of carprofen, ketoprofen and fenoprofen in dogs. V European ISSX Meeting Tours, France, 1993."}, {"key": "10.1002/chir.530070806-BIB38", "author": "Delatour", "volume": "145", "first-page": "551", "year": "1994", "journal-title": "Rev. Med. Vet."}, {"key": "10.1002/chir.530070806-BIB39", "author": "Evans", "volume": "42", "first-page": "237", "year": "1992", "journal-title": "Eur. J. Clin. Pharmacol."}, {"key": "10.1002/chir.530070806-BIB40", "author": "Dubois", "volume": "5", "first-page": "126", "year": "1993", "journal-title": "Chirality"}, {"key": "10.1002/chir.530070806-BIB41", "author": "Hayball", "volume": "3", "first-page": "460", "year": "1991", "journal-title": "Chirality"}, {"key": "10.1002/chir.530070806-BIB42", "author": "Hayball", "volume": "36", "first-page": "185", "year": "1993", "journal-title": "Br. J. Clin. Pharmacol.", "DOI": "10.1111/j.1365-2125.1993.tb04215.x", "doi-asserted-by": "crossref"}, {"key": "10.1002/chir.530070806-BIB43", "author": "Menzel", "volume": "5", "first-page": "422", "year": "1993", "journal-title": "Chirality"}, {"key": "10.1002/chir.530070806-BIB44", "author": "Vane", "volume": "231", "first-page": "232", "year": "1971", "journal-title": "Nature (London)", "DOI": "10.1038/newbio231232a0", "doi-asserted-by": "crossref"}, {"key": "10.1002/chir.530070806-BIB45", "author": "Short", "year": "1994", "unstructured": "The effect of ketoprofen on a soft-tissue inflammation model of thoroughbred horses. In: 6th International Congress?Edinburgh 1994 European Association for Veterinary Pharmacology and Toxicology, Edinburgh. Lees, P., ed. 1994: 151."}, {"key": "10.1002/chir.530070806-BIB46", "author": "Landoni", "volume": "27", "first-page": "247", "year": "1995", "journal-title": "Equine Vet. J."}, {"key": "10.1002/chir.530070806-BIB47", "author": "Julou", "volume": "14", "first-page": "33", "year": "1983", "journal-title": "Scand. J. Rheum."}, {"key": "10.1002/chir.530070806-BIB48", "author": "Landoni", "volume": "56", "first-page": "786", "year": "1995", "journal-title": "Am. J. Vet. Res."}, {"key": "10.1002/chir.530070806-BIB49", "author": "Landoni", "unstructured": "Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves applying PK/PD modelling. Res. Vet. Sci. (in press)."}, {"key": "10.1002/chir.530070806-BIB50", "author": "Villaneuva", "volume": "35", "first-page": "235", "year": "1993", "journal-title": "Br. J. Clin. Pharmacol.", "DOI": "10.1111/j.1365-2125.1993.tb05690.x", "doi-asserted-by": "crossref"}, {"key": "10.1002/chir.530070806-BIB51", "author": "Kantor", "volume": "6", "first-page": "92", "year": "1986", "journal-title": "Pharmacotherapy", "DOI": "10.1002/j.1875-9114.1986.tb03459.x", "doi-asserted-by": "crossref"}, {"key": "10.1002/chir.530070806-BIB52", "author": "Dray", "volume": "16", "first-page": "99", "year": "1993", "journal-title": "TIPS"}], "container-title": ["Chirality"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fchir.530070806", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/chir.530070806", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 1]], "date-time": "2018-08-01T00:04:49Z", "timestamp": 1533081889000}, "score": 22.536394, "issued": {"date-parts": [[1995]]}, "references-count": 52, "journal-issue": {"published-print": {"date-parts": [[1995]]}, "issue": "8"}, "URL": "http://dx.doi.org/10.1002/chir.530070806", "relation": {"cites": []}, "ISSN": ["0899-0042", "1520-636X"], "issn-type": [{"value": "0899-0042", "type": "print"}, {"value": "1520-636X", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T07:54:06Z", "timestamp": 1574236446594}, "reference-count": 28, "publisher": "Elsevier BV", "issue": "7", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1985, 7, 1]], "date-time": "1985-07-01T00:00:00Z", "timestamp": 489024000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Pharmaceutical Sciences"], "published-print": {"date-parts": [[1985, 7]]}, "DOI": "10.1002/jps.2600740703", "type": "journal-article", "created": {"date-parts": [[2006, 10, 14]], "date-time": "2006-10-14T21:08:03Z", "timestamp": 1160860083000}, "page": "711-717", "source": "Crossref", "is-referenced-by-count": 14, "title": ["Integrated Pharmacokinetics and Pharmacodynamics of Atropine in Healthy Humans II: Pharmacodynamics"], "prefix": "10.1016", "volume": "74", "author": [{"given": "Peter H.", "family": "Hinderling", "sequence": "first", "affiliation": []}, {"given": "Ursula", "family": "Gundert-Remy", "sequence": "additional", "affiliation": []}, {"given": "Olga", "family": "Schmidliny", "sequence": "additional", "affiliation": []}, {"given": "G\u00fcnther", "family": "Heinzel", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Journal of Pharmaceutical Sciences"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0022354915467851?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0022354915467851?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 21]], "date-time": "2019-04-21T19:30:25Z", "timestamp": 1555875025000}, "score": 22.385353, "issued": {"date-parts": [[1985, 7]]}, "references-count": 28, "journal-issue": {"published-print": {"date-parts": [[1985, 7]]}, "issue": "7"}, "alternative-id": ["S0022354915467851"], "URL": "http://dx.doi.org/10.1002/jps.2600740703", "ISSN": ["0022-3549"], "issn-type": [{"value": "0022-3549", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T16:16:53Z", "timestamp": 1574785013207}, "reference-count": 60, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2017, 6, 1]], "date-time": "2017-06-01T00:00:00Z", "timestamp": 1496275200000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "start": {"date-parts": [[2017, 2, 28]], "date-time": "2017-02-28T00:00:00Z", "timestamp": 1488240000000}, "delay-in-days": 0, "content-version": "vor"}], "funder": [{"name": "USL", "award": []}], "content-domain": {"domain": ["epilepsybehavior.com", "clinicalkey.jp", "clinicalkey.com", "clinicalkey.es", "clinicalkey.fr", "clinicalkey.com.au", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Epilepsy & Behavior"], "published-print": {"date-parts": [[2017, 6]]}, "DOI": "10.1016/j.yebeh.2017.02.023", "type": "journal-article", "created": {"date-parts": [[2017, 5, 23]], "date-time": "2017-05-23T04:02:39Z", "timestamp": 1495512159000}, "page": "51-59", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults"], "prefix": "10.1016", "volume": "71", "author": [{"given": "Alexander K.", "family": "Berg", "sequence": "first", "affiliation": []}, {"given": "Michael J.", "family": "Myrvik", "sequence": "additional", "affiliation": []}, {"given": "Peter J.", "family": "Van Ess", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Epilepsy & Behavior"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1525505017300847?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1525505017300847?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 4]], "date-time": "2019-04-04T11:53:11Z", "timestamp": 1554378791000}, "score": 22.017189, "issued": {"date-parts": [[2017, 6]]}, "references-count": 60, "alternative-id": ["S1525505017300847"], "URL": "http://dx.doi.org/10.1016/j.yebeh.2017.02.023", "ISSN": ["1525-5050"], "issn-type": [{"value": "1525-5050", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults", "name": "articletitle", "label": "Article Title"}, {"value": "Epilepsy & Behavior", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.yebeh.2017.02.023", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2017 The Authors. Published by Elsevier Inc.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T19:59:04Z", "timestamp": 1574539144186}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 11]]}, "DOI": "10.1158/1535-7163.targ-13-b212", "type": "proceedings-article", "created": {"date-parts": [[2014, 8, 14]], "date-time": "2014-08-14T22:27:17Z", "timestamp": 1408055237000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 4, "title": ["Abstract B212: Integrating the pre-clinical pharmacokinetic, pharmacodynamics, and efficacy data for AZD9291, an oral, irreversible inhibitor of EGFR activating (EGFRm+) and resistant (EGFRm+/T790M) mutations and an active metabolite to predict the human pharmacokinetics and potential efficacious dose in patients."], "prefix": "10.1158", "author": [{"given": "Peter", "family": "Ballard", "sequence": "first", "affiliation": []}, {"given": "Susan", "family": "Ashton", "sequence": "additional", "affiliation": []}, {"given": "Darren", "family": "Cross", "sequence": "additional", "affiliation": []}, {"given": "Richard", "family": "Dimelow", "sequence": "additional", "affiliation": []}, {"given": "James", "family": "Yates", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 1, 30]]}, "event": {"name": "Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA"}, "container-title": ["Pharmacokinetics and Pharmacodynamics"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1535-7163.TARG-13-B212", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 9]], "date-time": "2019-05-09T19:38:56Z", "timestamp": 1557430736000}, "score": 21.829508, "issued": {"date-parts": [[2013, 11]]}, "references-count": 0, "alternative-id": ["10.1158/1535-7163.TARG-13-B212"], "URL": "http://dx.doi.org/10.1158/1535-7163.targ-13-b212"}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T07:54:04Z", "timestamp": 1574236444128}, "reference-count": 37, "publisher": "Elsevier BV", "issue": "7", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1985, 7, 1]], "date-time": "1985-07-01T00:00:00Z", "timestamp": 489024000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Pharmaceutical Sciences"], "published-print": {"date-parts": [[1985, 7]]}, "DOI": "10.1002/jps.2600740702", "type": "journal-article", "created": {"date-parts": [[2006, 10, 14]], "date-time": "2006-10-14T21:08:03Z", "timestamp": 1160860083000}, "page": "703-710", "source": "Crossref", "is-referenced-by-count": 35, "title": ["Integrated Pharmacokinetics and Pharmacodynamics of Atropine in Healthy Humans I: Pharmacokinetics"], "prefix": "10.1016", "volume": "74", "author": [{"given": "Peter H.", "family": "Hinderling", "sequence": "first", "affiliation": []}, {"given": "Ursula", "family": "Gundert-Remy", "sequence": "additional", "affiliation": []}, {"given": "Olga", "family": "Schmidlin", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Journal of Pharmaceutical Sciences"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0022354915467863?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0022354915467863?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 21]], "date-time": "2019-04-21T19:30:25Z", "timestamp": 1555875025000}, "score": 21.70231, "issued": {"date-parts": [[1985, 7]]}, "references-count": 37, "journal-issue": {"published-print": {"date-parts": [[1985, 7]]}, "issue": "7"}, "alternative-id": ["S0022354915467863"], "URL": "http://dx.doi.org/10.1002/jps.2600740702", "ISSN": ["0022-3549"], "issn-type": [{"value": "0022-3549", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T03:04:10Z", "timestamp": 1574823850587}, "reference-count": 64, "publisher": "Springer Science and Business Media LLC", "issue": "3", "license": [{"URL": "http://creativecommons.org/licenses/by-nc/4.0", "start": {"date-parts": [[2016, 7, 28]], "date-time": "2016-07-28T00:00:00Z", "timestamp": 1469664000000}, "delay-in-days": 0, "content-version": "unspecified"}], "funder": [{"DOI": "10.13039/100008349", "name": "Boehringer Ingelheim", "doi-asserted-by": "publisher", "award": []}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Clin Pharmacokinet"], "published-print": {"date-parts": [[2017, 3]]}, "DOI": "10.1007/s40262-016-0440-1", "type": "journal-article", "created": {"date-parts": [[2016, 7, 28]], "date-time": "2016-07-28T15:01:58Z", "timestamp": 1469718118000}, "page": "235-250", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 29, "title": ["Clinical Pharmacokinetics and Pharmacodynamics of Afatinib"], "prefix": "10.1007", "volume": "56", "author": [{"given": "Sven", "family": "Wind", "sequence": "first", "affiliation": []}, {"given": "David", "family": "Schnell", "sequence": "additional", "affiliation": []}, {"given": "Thomas", "family": "Ebner", "sequence": "additional", "affiliation": []}, {"given": "Matthias", "family": "Freiwald", "sequence": "additional", "affiliation": []}, {"given": "Peter", "family": "Stopfer", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 7, 28]]}, "reference": [{"issue": "Suppl 4", "key": "440_CR1", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1634/theoncologist.7-suppl_4-31", "volume": "7", "author": "CL Arteaga", "year": "2002", "unstructured": "Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002;7(Suppl 4):31\u20139.", "journal-title": "Oncologist."}, {"key": "440_CR2", "doi-asserted-by": "crossref", "first-page": "1160", "DOI": "10.1056/NEJMra0707704", "volume": "358", "author": "F Ciardiello", "year": "2008", "unstructured": "Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160\u201374.", "journal-title": "N Engl J Med"}, {"key": "440_CR3", "doi-asserted-by": "crossref", "first-page": "169", "DOI": "10.1038/nrc2088", "volume": "7", "author": "SV Sharma", "year": "2007", "unstructured": "Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169\u201381.", "journal-title": "Nat Rev Cancer"}, {"key": "440_CR4", "doi-asserted-by": "crossref", "first-page": "947", "DOI": "10.1056/NEJMoa0810699", "volume": "361", "author": "TS Mok", "year": "2009", "unstructured": "Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u201357.", "journal-title": "N Engl J Med"}, {"key": "440_CR5", "doi-asserted-by": "crossref", "first-page": "121", "DOI": "10.1016/S1470-2045(09)70364-X", "volume": "11", "author": "T Mitsudomi", "year": "2010", "unstructured": "Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121\u20138.", "journal-title": "Lancet Oncol."}, {"key": "440_CR6", "doi-asserted-by": "crossref", "first-page": "2380", "DOI": "10.1056/NEJMoa0909530", "volume": "362", "author": "M Maemondo", "year": "2010", "unstructured": "Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380\u20138.", "journal-title": "N Engl J Med"}, {"key": "440_CR7", "doi-asserted-by": "crossref", "first-page": "735", "DOI": "10.1016/S1470-2045(11)70184-X", "volume": "12", "author": "C Zhou", "year": "2011", "unstructured": "Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735\u201342.", "journal-title": "Lancet Oncol."}, {"key": "440_CR8", "doi-asserted-by": "crossref", "first-page": "239", "DOI": "10.1016/S1470-2045(11)70393-X", "volume": "13", "author": "R Rosell", "year": "2012", "unstructured": "Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u201346.", "journal-title": "Lancet Oncol."}, {"key": "440_CR9", "doi-asserted-by": "crossref", "first-page": "7526", "DOI": "10.1126/scitranslmed.3002003", "volume": "3", "author": "LV Sequist", "year": "2011", "unstructured": "Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:7526.", "journal-title": "Sci Transl Med."}, {"key": "440_CR10", "doi-asserted-by": "crossref", "first-page": "2240", "DOI": "10.1158/1078-0432.CCR-12-2246", "volume": "19", "author": "HA Yu", "year": "2013", "unstructured": "Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240\u20137.", "journal-title": "Clin Cancer Res"}, {"key": "440_CR11", "doi-asserted-by": "crossref", "first-page": "5764", "DOI": "10.1158/1078-0432.CCR-06-0714", "volume": "12", "author": "T Kosaka", "year": "2006", "unstructured": "Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res. 2006;12:5764\u20139.", "journal-title": "Clin Cancer Res"}, {"key": "440_CR12", "doi-asserted-by": "crossref", "first-page": "2070", "DOI": "10.1073/pnas.0709662105", "volume": "105", "author": "CH Yun", "year": "2008", "unstructured": "Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA. 2008;105:2070\u20135.", "journal-title": "Proc Natl Acad Sci USA."}, {"key": "440_CR13", "first-page": "12404", "volume": "7", "author": "SG Wu", "year": "2016", "unstructured": "Wu SG, Liu YN, Tsai MF, et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 2016;7:12404\u201313.", "journal-title": "Oncotarget."}, {"key": "440_CR14", "doi-asserted-by": "crossref", "first-page": "481", "DOI": "10.1016/j.ejca.2006.11.007", "volume": "43", "author": "A Reid", "year": "2007", "unstructured": "Reid A, Vidal L, Shaw H, et al. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer. 2007;43:481\u20139.", "journal-title": "Eur J Cancer"}, {"key": "440_CR15", "doi-asserted-by": "crossref", "first-page": "4702", "DOI": "10.1038/onc.2008.109", "volume": "27", "author": "D Li", "year": "2008", "unstructured": "Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27:4702\u201311.", "journal-title": "Oncogene"}, {"key": "440_CR16", "doi-asserted-by": "crossref", "first-page": "342", "DOI": "10.1124/jpet.112.197756", "volume": "343", "author": "F Solca", "year": "2012", "unstructured": "Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343:342\u201350.", "journal-title": "J Pharmacol Exp Ther"}, {"key": "440_CR17", "unstructured": "Boehringer Ingelheim. Gilotrif [prescribing information] (2016) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT. http://www.gilotrif.com/ . Accessed 7 Jun 2016."}, {"key": "440_CR18", "unstructured": "European Medicines Agency. Giotrif: summary of product characteristics, version 24 May 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002280/WC500152392.pdf . Accessed 7Jun 2016."}, {"key": "440_CR19", "doi-asserted-by": "crossref", "first-page": "3327", "DOI": "10.1200/JCO.2012.44.2806", "volume": "31", "author": "LV Sequist", "year": "2013", "unstructured": "Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327\u201334.", "journal-title": "J Clin Oncol"}, {"key": "440_CR20", "doi-asserted-by": "crossref", "first-page": "213", "DOI": "10.1016/S1470-2045(13)70604-1", "volume": "15", "author": "YL Wu", "year": "2014", "unstructured": "Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213\u201322.", "journal-title": "Lancet Oncol."}, {"key": "440_CR21", "doi-asserted-by": "crossref", "first-page": "141", "DOI": "10.1016/S1470-2045(14)71173-8", "volume": "16", "author": "JC Yang", "year": "2015", "unstructured": "Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141\u201351.", "journal-title": "Lancet Oncol."}, {"key": "440_CR22", "doi-asserted-by": "crossref", "first-page": "897", "DOI": "10.1016/S1470-2045(15)00006-6", "volume": "16", "author": "JC Soria", "year": "2015", "unstructured": "Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015;16:897\u2013907.", "journal-title": "Lancet Oncol."}, {"key": "440_CR23", "unstructured": "European Medicines Agency. Giotrif. Procedural steps taken and scientific information after the authorisation. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/002280/WC500177054.pdf . Accessed 19 July 2016."}, {"key": "440_CR24", "doi-asserted-by": "crossref", "first-page": "505", "DOI": "10.1007/s00210-014-0967-3", "volume": "387", "author": "H Modjtahedi", "year": "2014", "unstructured": "Modjtahedi H, Cho BC, Michel MC, et al. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol. 2014;387:505\u201321.", "journal-title": "Naunyn Schmiedebergs Arch Pharmacol."}, {"key": "440_CR25", "unstructured": "European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment report for Giotrif (afatinib). 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002280/WC500152394.pdf . Accessed 17 Mar 2016."}, {"key": "440_CR26", "unstructured": "FDA Center for Drug Evaluation and Research. Afatinib clinical pharmacology NDA review. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292Orig1s000ClinPharmR.pdfAccessed 17 Mar 2016."}, {"key": "440_CR27", "unstructured": "FDA Center for Drug Evaluation and Research (CDER). Guidance for industry. Drug interaction studies: study design, data analysis, implications for dosing, and labeling recommendations. US FDA draft guidance. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf . Accessed 17 Mar 2016."}, {"key": "440_CR28", "unstructured": "FDA Center for Drug Evaluation and Research. Afatinib pharmacology NDA# 201292 review. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292Orig1s000PharmR.pdf . Accessed 17 Mar 2016."}, {"key": "440_CR29", "doi-asserted-by": "crossref", "first-page": "80", "DOI": "10.1038/sj.bjc.6604108", "volume": "98", "author": "FA Eskens", "year": "2008", "unstructured": "Eskens FA, Mom CH, Planting AS, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008;98:80\u20135.", "journal-title": "Br J Cancer"}, {"key": "440_CR30", "doi-asserted-by": "crossref", "first-page": "3965", "DOI": "10.1200/JCO.2009.26.7278", "volume": "28", "author": "TA Yap", "year": "2010", "unstructured": "Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28:3965\u201372.", "journal-title": "J Clin Oncol"}, {"key": "440_CR31", "doi-asserted-by": "crossref", "first-page": "399", "DOI": "10.1007/s10637-012-9890-y", "volume": "31", "author": "J Marshall", "year": "2013", "unstructured": "Marshall J, Hwang J, Eskens FA, et al. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs. 2013;31:399\u2013408.", "journal-title": "Invest New Drugs"}, {"key": "440_CR32", "doi-asserted-by": "crossref", "first-page": "409", "DOI": "10.1007/s10637-012-9904-9", "volume": "31", "author": "MS Gordon", "year": "2013", "unstructured": "Gordon MS, Mendelson DS, Gross M, et al. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013;31:409\u201316.", "journal-title": "Invest New Drugs"}, {"key": "440_CR33", "doi-asserted-by": "crossref", "first-page": "1213", "DOI": "10.1007/s00280-013-2286-7", "volume": "72", "author": "LR Molife", "year": "2013", "unstructured": "Molife LR, Rudman SM, Alam S, et al. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemother Pharmacol. 2013;72:1213\u201322.", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "440_CR34", "doi-asserted-by": "crossref", "first-page": "1101", "DOI": "10.1007/s40262-013-0091-4", "volume": "52", "author": "S Wind", "year": "2013", "unstructured": "Wind S, Schmid M, Erhardt J, et al. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet. 2013;52:1101\u20139.", "journal-title": "Clin Pharmacokinet"}, {"key": "440_CR35", "doi-asserted-by": "crossref", "first-page": "759", "DOI": "10.1007/s00280-014-2403-2", "volume": "73", "author": "M Freiwald", "year": "2014", "unstructured": "Freiwald M, Schmid U, Fleury A, et al. Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Cancer Chemother Pharmacol. 2014;73:759\u201370.", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "440_CR36", "unstructured": "Boehringer Ingelheim. Relative bioavailability of a single dose of 20\u00a0mg BIBW 2992 administered as tablet (final formulation) compared to BIBW 2992 drinking solution and BIBW 2992 tablet (trial formulation II) following oral administration to healthy male volunteers (an open-label, randomised, single-dose, three-way crossover phase I study). Trial No. 1200.35. http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1200/1200.35_U09-2233-02.pdf . Accessed 17 Mar 2016."}, {"key": "440_CR37", "unstructured": "FDA Center for Drug Evaluation and Research (CDER). Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. US FDA draft guidance. 2002. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126833.pdf . Accessed 17 Mar 2016."}, {"key": "440_CR38", "doi-asserted-by": "crossref", "first-page": "267", "DOI": "10.1007/s00280-014-2484-y", "volume": "74", "author": "D Schnell", "year": "2014", "unstructured": "Schnell D, Buschke S, Fuchs H, et al. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemother Pharmacol. 2014;74:267\u201375.", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "440_CR39", "unstructured": "Wiebe S, Schnell D, Kulzer R, et al. Influence of renal impairment on the pharmacokinetics of afatinib: an open-label, single-centre study. Eur J Drug Metab Pharmacokinet. 2016. doi: 10.1007/s13318-016-0359-9 .", "DOI": "10.1007/s13318-016-0359-9", "doi-asserted-by": "publisher"}, {"key": "440_CR40", "doi-asserted-by": "crossref", "first-page": "1051", "DOI": "10.1007/s00280-011-1803-9", "volume": "69", "author": "P Stopfer", "year": "2012", "unstructured": "Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012;69:1051\u201361.", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "440_CR41", "unstructured": "US FDA Center for Drug Evaluation and Research. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry. Pharmacokinetics in patients with impaired renal function: study design, data analysis, and impact on dosing and labeling. 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf . Accessed 2 Jan 2016."}, {"key": "440_CR42", "doi-asserted-by": "crossref", "first-page": "898", "DOI": "10.1038/clpt.2008.59", "volume": "83", "author": "TD Nolin", "year": "2008", "unstructured": "Nolin TD, Naud J, Leblond FA, et al. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008;83:898\u2013903.", "journal-title": "Clin Pharmacol Ther"}, {"key": "440_CR43", "doi-asserted-by": "crossref", "first-page": "305", "DOI": "10.1038/clpt.2008.208", "volume": "85", "author": "Y Zhang", "year": "2009", "unstructured": "Zhang Y, Zhang L, Abraham S, et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther. 2009;85:305\u201311.", "journal-title": "Clin Pharmacol Ther."}, {"key": "440_CR44", "unstructured": "Moran T, Palmero R, Provencio M, et al. A Phase Ib open label clinical trial of continuous once daily oral afatinib (A) plus sirolimus (S) in patients (Pts) with EGFR mutation positive (EGFR M\u00a0+) NSCLC and/or disease progression following prior erlotinib (E) or gefitinib (G) [abstract no. 1248PA]. Ann Oncol. 2014;25:iv437.", "DOI": "10.1093/annonc/mdu349.27", "doi-asserted-by": "crossref"}, {"key": "440_CR45", "doi-asserted-by": "crossref", "first-page": "173", "DOI": "10.1007/s40261-013-0161-2", "volume": "34", "author": "S Wind", "year": "2014", "unstructured": "Wind S, Giessmann T, Jungnik A, et al. Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clin Drug Investig. 2014;34:173\u201382.", "journal-title": "Clin Drug Investig"}, {"key": "440_CR46", "doi-asserted-by": "crossref", "first-page": "430", "DOI": "10.1080/00498250902846252", "volume": "39", "author": "T Tachibana", "year": "2009", "unstructured": "Tachibana T, Kato M, Watanabe T, et al. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica. 2009;39:430\u201343.", "journal-title": "Xenobiotica"}, {"key": "440_CR47", "doi-asserted-by": "crossref", "first-page": "45", "DOI": "10.1186/s40064-015-1601-7", "volume": "5", "author": "K Gunzer", "year": "2016", "unstructured": "Gunzer K, Joly F, Ferrero JM, et al. A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. Springerplus. 2016;5:45.", "journal-title": "Springerplus."}, {"key": "440_CR48", "doi-asserted-by": "crossref", "first-page": "2275", "DOI": "10.1016/j.ejca.2015.07.041", "volume": "51", "author": "A Suder", "year": "2015", "unstructured": "Suder A, Ang JE, Kyle F, et al. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer. 2015;51:2275\u201384.", "journal-title": "Eur J Cancer"}, {"key": "440_CR49", "doi-asserted-by": "crossref", "first-page": "1226", "DOI": "10.1007/s10637-014-0139-9", "volume": "32", "author": "QS Chu", "year": "2014", "unstructured": "Chu QS, Sangha R, Hotte SJ, et al. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Invest New Drugs. 2014;32:1226\u201335.", "journal-title": "Invest New Drugs"}, {"key": "440_CR50", "doi-asserted-by": "crossref", "first-page": "734", "DOI": "10.1007/s10637-012-9880-0", "volume": "31", "author": "AH Awada", "year": "2013", "unstructured": "Awada AH, Dumez H, Hendlisz A, et al. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Invest New Drugs. 2013;31:734\u201341.", "journal-title": "Invest New Drugs"}, {"key": "440_CR51", "doi-asserted-by": "crossref", "first-page": "739", "DOI": "10.1007/s00280-015-2826-4", "volume": "76", "author": "H Mukai", "year": "2015", "unstructured": "Mukai H, Masuda N, Ishiguro H, et al. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. Cancer Chemother Pharmacol. 2015;76:739\u201350.", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "440_CR52", "first-page": "430", "volume": "17", "author": "DA Reardon", "year": "2015", "unstructured": "Reardon DA, Nabors LB, Mason WP, et al. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2015;17:430\u20139.", "journal-title": "Neuro Oncol."}, {"key": "440_CR53", "doi-asserted-by": "crossref", "first-page": "1057", "DOI": "10.1007/s10549-012-2003-y", "volume": "133", "author": "NU Lin", "year": "2012", "unstructured": "Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012;133:1057\u201365.", "journal-title": "Breast Cancer Res Treat"}, {"key": "440_CR54", "doi-asserted-by": "crossref", "first-page": "2737", "DOI": "10.1158/1078-0432.CCR-14-1812", "volume": "21", "author": "A Ring", "year": "2015", "unstructured": "Ring A, Wheatley D, Hatcher H, et al. Phase I study to assess the combination of afatinib with trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Clin Cancer Res. 2015;21:2737\u201344.", "journal-title": "Clin Cancer Res"}, {"key": "440_CR55", "doi-asserted-by": "crossref", "first-page": "1479", "DOI": "10.2217/fon.15.50", "volume": "11", "author": "MS Gordon", "year": "2015", "unstructured": "Gordon MS, Springett GM, Su YB, et al. A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors. Future Oncol. 2015;11:1479\u201391.", "journal-title": "Future Oncol."}, {"key": "440_CR56", "unstructured": "Boehringer Ingelheim. A phase I open label trial of continuous dosing with BIBW 2992 combined with paclitaxel and BIBW 2992 combined with paclitaxel and bevacizumab, BIBW 2992 combined with carboplatin and BIBW 2992 combined with paclitaxel and carboplatin in patients with advanced solid tumours. Trial No. 1200.12. http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1200/1200.12_c01802594-02_DR.pdf . Accessed 17 Mar 2016."}, {"key": "440_CR57", "doi-asserted-by": "crossref", "first-page": "1392", "DOI": "10.1093/annonc/mds633", "volume": "24", "author": "JB Vermorken", "year": "2013", "unstructured": "Vermorken JB, Rottey S, Ehrnrooth E, et al. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Ann Oncol. 2013;24:1392\u2013400.", "journal-title": "Ann Oncol"}, {"key": "440_CR58", "doi-asserted-by": "crossref", "first-page": "920", "DOI": "10.1002/j.1875-9114.2012.01117", "volume": "32", "author": "WP Petros", "year": "2012", "unstructured": "Petros WP, Younis IR, Ford JN, et al. Effects of tobacco smoking and nicotine on cancer treatment. Pharmacotherapy. 2012;32:920\u201331.", "journal-title": "Pharmacotherapy."}, {"key": "440_CR59", "doi-asserted-by": "crossref", "first-page": "539", "DOI": "10.1016/S1470-2045(12)70086-4", "volume": "13", "author": "JC Yang", "year": "2012", "unstructured": "Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13:539\u201348.", "journal-title": "Lancet Oncol."}, {"key": "440_CR60", "doi-asserted-by": "crossref", "first-page": "528", "DOI": "10.1016/S1470-2045(12)70087-6", "volume": "13", "author": "VA Miller", "year": "2012", "unstructured": "Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13:528\u201338.", "journal-title": "Lancet Oncol."}, {"key": "440_CR61", "doi-asserted-by": "crossref", "first-page": "891", "DOI": "10.1007/s00280-011-1738-1", "volume": "69", "author": "H Murakami", "year": "2012", "unstructured": "Murakami H, Tamura T, Takahashi T, et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol. 2012;69:891\u20139.", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "440_CR62", "doi-asserted-by": "crossref", "first-page": "3335", "DOI": "10.1200/JCO.2012.45.0981", "volume": "31", "author": "N Katakami", "year": "2013", "unstructured": "Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013;31:3335\u201341.", "journal-title": "J Clin Oncol"}, {"key": "440_CR63", "unstructured": "Yang JC, Ahn MJ, Dickgreber NJ, et al. Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(15_Suppl):8073."}, {"key": "440_CR64", "doi-asserted-by": "crossref", "first-page": "103", "DOI": "10.1016/j.lungcan.2011.01.016", "volume": "74", "author": "X Song", "year": "2011", "unstructured": "Song X, Varker H, Eichelbaum M, et al. Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes. Lung Cancer. 2011;74:103\u201311.", "journal-title": "Lung Cancer"}], "container-title": ["Clinical Pharmacokinetics"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s40262-016-0440-1.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s40262-016-0440-1/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s40262-016-0440-1", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s40262-016-0440-1.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 24]], "date-time": "2017-06-24T19:26:07Z", "timestamp": 1498332367000}, "score": 21.70231, "issued": {"date-parts": [[2016, 7, 28]]}, "references-count": 64, "journal-issue": {"published-print": {"date-parts": [[2017, 3]]}, "issue": "3"}, "alternative-id": ["440"], "URL": "http://dx.doi.org/10.1007/s40262-016-0440-1", "relation": {"cites": []}, "ISSN": ["0312-5963", "1179-1926"], "issn-type": [{"value": "0312-5963", "type": "print"}, {"value": "1179-1926", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T15:34:39Z", "timestamp": 1574264079131}, "reference-count": 0, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "6", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Anesthesiology"], "published-print": {"date-parts": [[1982, 12]]}, "DOI": "10.1097/00000542-198212000-00005", "type": "journal-article", "created": {"date-parts": [[2008, 11, 27]], "date-time": "2008-11-27T11:18:30Z", "timestamp": 1227784710000}, "page": "458-467", "source": "Crossref", "is-referenced-by-count": 94, "title": ["Pharmacodynamics and Pharmacokinetics of Methadone during the Perioperative Period"], "prefix": "10.1097", "volume": "57", "author": [{"given": "Geoffrey K.", "family": "Gourlay", "sequence": "first", "affiliation": []}, {"given": "Peter R.", "family": "Wilson", "sequence": "additional", "affiliation": []}, {"given": "Christopher J.", "family": "Glynn", "sequence": "additional", "affiliation": []}], "member": "276", "container-title": ["Anesthesiology"], "language": "en", "link": [{"URL": "http://journals.lww.com/anesthesiology/Fulltext/10.1097/00000542-198212000-00005", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 11, 29]], "date-time": "2018-11-29T12:05:30Z", "timestamp": 1543493130000}, "score": 21.399126, "subtitle": [""], "issued": {"date-parts": [[1982, 12]]}, "references-count": 0, "journal-issue": {"issue": "6"}, "URL": "http://dx.doi.org/10.1097/00000542-198212000-00005", "ISSN": ["0003-3022"], "issn-type": [{"value": "0003-3022", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T18:20:17Z", "timestamp": 1574101217491}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "3", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1996, 7, 1]], "date-time": "1996-07-01T00:00:00Z", "timestamp": 836179200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Controlled Release"], "published-print": {"date-parts": [[1996, 7]]}, "DOI": "10.1016/0168-3659(96)81464-7", "type": "journal-article", "created": {"date-parts": [[2002, 7, 25]], "date-time": "2002-07-25T18:51:06Z", "timestamp": 1027623066000}, "page": "328", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Pharmacokinetics: Regulatory, industrial, academic, perspectives second edition"], "prefix": "10.1016", "volume": "40", "author": [{"given": "Peter R.", "family": "Gwilt", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Journal of Controlled Release"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:0168365996814647?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:0168365996814647?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 23]], "date-time": "2019-04-23T08:59:47Z", "timestamp": 1556009987000}, "score": 21.257627, "issued": {"date-parts": [[1996, 7]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1996, 7]]}, "issue": "3"}, "alternative-id": ["0168365996814647"], "URL": "http://dx.doi.org/10.1016/0168-3659(96)81464-7", "ISSN": ["0168-3659"], "issn-type": [{"value": "0168-3659", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T18:48:29Z", "timestamp": 1575226109318}, "reference-count": 0, "publisher": "American Thoracic Society", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2010, 5]]}, "DOI": "10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5397", "type": "proceedings-article", "created": {"date-parts": [[2013, 5, 23]], "date-time": "2013-05-23T12:38:47Z", "timestamp": 1369312727000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Single-Dose, First-in-Human Study Of AMG 853: Pharmacokinetics, Pharmacodynamics, And Safety In Healthy Adults"], "prefix": "10.1164", "author": [{"given": "Christopher", "family": "Banfield", "sequence": "first", "affiliation": []}, {"given": "Jane", "family": "Parnes", "sequence": "additional", "affiliation": []}, {"given": "Maurice", "family": "Emery", "sequence": "additional", "affiliation": []}, {"given": "Liyun", "family": "Ni", "sequence": "additional", "affiliation": []}, {"given": "Nan", "family": "Zhang", "sequence": "additional", "affiliation": []}, {"given": "Peter", "family": "Hodsman", "sequence": "additional", "affiliation": []}], "member": "19", "event": {"name": "American Thoracic Society 2010 International Conference, May 14-19, 2010 \u2022 New Orleans"}, "container-title": ["D21. ASTHMA THERAPY: NEW TARGETS, NEW TRICKS"], "deposited": {"date-parts": [[2013, 5, 23]], "date-time": "2013-05-23T12:38:50Z", "timestamp": 1369312730000}, "score": 21.224802, "issued": {"date-parts": [[2010, 5]]}, "references-count": 0, "alternative-id": ["10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A5397", "10.1164/ajrccm-conference.2010.D021"], "URL": "http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5397"}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}